Neurocognition and Disability in Patients with Schizophrenia compared with Healthy Controls by Sheerin Fathima, A S
 
 
NEUROCOGNITION AND DISABILITY IN PATIENTS WITH 
SCHIZOPHRENIA COMPARED WITH HEALTHY CONTROLS 
 
Dissertation submitted by 
 
Dr. A. S. SHEERIN FATHIMA, M.B.B.S., 
 
In partial fulfillment of the regulations required for the degree of 
 
DOCTOR OF MEDICINE IN PSYCHIATRY 
 
 
Under the guidance of 
Dr. I. ANAND 
Professor  
                               Department of Psychiatry  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
THE TAMIL NADU DR. M.G.R. MEDICAL UNIVERSITY  
 
 
 
 
 
 
 
 
 
 
 
 
PSG INSTITUTE OF MEDICAL SCIENCES AND RESEARCH 
 
COIMBATORE 
 
MAY – 2019
 
 
 
 
DECLARATION BY THE CANDIDATE 
 
 
 
I hereby declare that this dissertation entitled  “Neurocognition and Disability in 
patients with Schizophrenia compared with healthy controls” is a bonafide and 
genuine research work carried by me under the guidance of Dr. I. Anand, Professor 
in the Department of Psychiatry, PSGIMS & R, Coimbatore. 
 
 
 
 
 
 
 
 
 
PLACE: COIMBATORE                         Dr. SHEERIN FATHIMA A. S. 
 
 
DATE:                                                                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CERTIFICATE BY THE GUIDE 
 
 
This is to certify that this dissertation entitled “Neurocognition and Disability in 
patients with Schizophrenia compared with healthy controls” is a bonafide 
work done by Dr. SHEERIN FATHIMA A. S. in partial fulfillment of the 
requirement for the degree of M.D. (PSYCHIATRY) 
 
 
 
 
 
PLACE: COIMBATORE           DR. I. ANAND    D.P.M., M.D 
 
DATE:                               PROFESSOR 
 
     DEPARTMENT OF PSYCHIATRY 
 
                                                         PSGIMS&R 
 
 
 
 
 
 
ENDORSEMENT BY THE HOD/DEAN OF THE INSTITUTION 
 
This is to certify that this dissertation entitled “Neurocognition and Disability in 
patients with Schizophrenia compared with healthy controls” is a bonafide 
research work done by Dr. SHEERIN FATHIMA A. S. under the guidance of 
Dr. I. ANAND, Professor in the Department of Psychiatry, PSGIMS&R, 
Coimbatore. 
 
 
 
 
 
Dr. RAMALINGAM, M.D             Dr. G. RAGHUTHAMAN, M.D 
Dean                                             Professor and Head of the department, 
PSGIMS&R,                                        Department of Psychiatry, 
Coimbatore.                                          PSGIMS&R, Coimbatore 
 
 
DATE:     
 
PLACE:   COIMBATORE 
 
 
 
ACKNOWLEDGEMENT 
 
It is indeed a great pleasure to recall the people who have helped me in the 
completion of my dissertation. Naming all the people who have helped me in 
achieving this goal would be impossible, yet I attempt to thank a selected few who 
have helped me in diverse ways. 
I express my deepest gratitude and sincere thanks to my beloved teacher and 
Guide Dr. I. Anand, D.P.M., M.D (Psychiatry), Professor, Department of 
Psychiatry, PSGIMS&R, Coimbatore for his guidance, encouragement and 
unfaltering support that he has given during the process of this dissertation. 
I whole-heartedly thank Dr. Anuja Panicker Ph.D., Clinical Psychologist, 
PSGIMS&R, Coimbatore for her guidance and for teaching me the nuances of a 
proper neuropsychological assessment that made this study possible.  
 I express my heartfelt gratitude to Dr. G. Raghuthaman M.D., Head of the 
Department of Psychiatry and to all the Professors in the Department of Psychiatry, 
PSGIMS&R, Coimbatore for their immense support and valuable feedback given 
at the time of conception of this study. 
 
 
I sincerely thank the Nursing staff for their valued support and timely help 
rendered during this study.  
My sincere thanks to all the Post-graduate colleagues in the Department of 
Psychiatry, PSGIMS&R and my dearest friends for helping me and supporting me 
at all times. 
Finally, I thank all the participants of my study, who formed the backbone of 
this research and without whom this dissertation would not have been possible. 
 
 
 
 
PLACE: COIMBATORE   Dr. SHEERIN FATHIMA A. S. 
DATE:                                                             
 
 
 
 
 
 
 
 

 
 
CERTIFICATE – II 
 
 
This is to certify that this dissertation work titled “Neurocognition and 
Disability in patients with Schizophrenia compared with healthy 
controls” of the candidate Dr. SHEERIN FATHIMA A. S. with 
registration Number ..201628303..for the award of  M.D. degree in the 
branch of…PSYCHIATRY… I personally verified the urkund.com 
website for thepurpose of plagiarism Check. I found that the uploaded 
thesis filecontains from introduction to conclusion pages and result 
shows. 1 %…percentage of plagiarism in the dissertation. 
 
 
 
 
 
 
 
 
Guide & Supervisor sign with Seal. 
 
 INDEX 
 
 
S.No. 
 
TABLE OF CONTENTS 
 
PAGE NUMBER 
 
1.  
 
ABSTRACT 
 
1 
 
2.  
 
INTRODUCTION 
 
3 
 
3.  
 
REVIEW OF LITERATURE 
 
5 
 
4.  
 
RATIONALE FOR THE STUDY 
 
30 
 
5.  
 
AIMS & OBJECTIVES 
 
31 
 
6.  
 
METHODOLOGY 
 
32 
 
7.  
 
STATISTICAL ANALYSIS 
 
47 
 
8.  
 
RESULTS 
 
49 
 
9.  
 
DISCUSSION 
 
75 
 
10. 
 
STRENGTHS 
 
85 
 
11. 
 
LIMITATIONS 
 
87 
 
12. 
 
CONCLUSION 
 
88 
 
13. 
 
BIBLIOGRAPHY 
 
89 
 
14. 
 
ANNEXURE 
 
95 
 
 1 
ABSTRACT 
 
 
 
 
BACKGROUND:  
Majority of patients with schizophrenia have life-long disability in their social and 
occupational functioning. Cognitive impairment is recognized as an important domain 
of schizophrenia, with a wide range of deficits seen among patients with 
schizophrenia.  
 
 
AIM: 
The current study aimed at assessing the neurocognitive function in clinically stable 
schizophrenia patients, in comparison with age and gender matched controls. 
Secondary aim was to assess any correlation between neurocognitive deficits and 
duration of illness; neurocognitive deficits and disability among patients with 
schizophrenia. 
 
 
METHODOLOGY: 
20 clinically stable schizophrenics & 20 age and gender matched healthy controls 
were included in the study. Select 8 tests from the NIMHANS Neuropsychological 
battery was used to assess the neurocognitive functions such as attention, processing 
speed, verbal learning and memory, executive functions, visual memory and visuo-
spatial skills.  
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RESULTS: 
Results revealed a statistically significant difference between the two groups in the 
performance of all neurocognitive tests, with the schizophrenia patients group scoring 
lesser. Within the patient group, those with duration of illness < 2 years scored more 
on tasks for attention, verbal learning and memory and visual memory & had lower 
degree of disability, which were statistically significant.   
 
CONCLUSION: 
The current study emphasizes on the importance of assessing neurocognitive 
functions in all schizophrenia patients. Recently, cognitive remediation therapy is 
being done to improve the neurocognitive functioning which can have a significant 
implication on the overall well-being of the patient.  
 
KEY WORDS: neurocognition, cognitive deficits, schizophrenia, disability, 
functional, neuropsychological 
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INTRODUCTION 
Schizophrenia is a major mental illness posing a challenge to both who suffer from 
the disease as well as to those who are involved in treating the disease. It is 
considered to be one of the most puzzling diseases of the brain. Schizophrenia 
includes various domains of symptoms such as psychotic symptoms, deficits in 
cognitive functioning and significant psychosocial impairment.  Schizophrenic 
disorders are characterized by fundamental and characteristic distortions of thinking 
and perception, and by inappropriate or blunted affect. Clear consciousness and 
intellectual capacity are usually maintained, although certain cognitive deficits may 
evolve in the course of time. The course of the disorder usually shows great variation 
and is by no means inevitably chronic or deteriorating. 
 
Understanding the complex neural mechanisms that are involved in the disease 
process is essential for establishing the reason behind such widespread and significant 
impairment. It is also especially important to develop specific treatments such as drug 
targets or other therapeutic measures. The later years of 20
th
 century saw the rise of 
numerous antipsychotic medications that were developed to treat Schizophrenia. With 
the recent advancements in research, fundamental knowledge about the neural basis of 
the illness has been postulated. Studies are also being done on the possible genes 
involved, cellular or molecular mechanisms responsible for this disease. Thus, we can 
positively hope for new and advances treatment measures for this debilitating and 
deteriorating disorder.  
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An important development in the understanding of the psychopathology of 
schizophrenia is an appreciation of the importance of cognitive impairment in the 
disorder. Tremendous effort has gone into identifying the type and extent of 
impairments and its associated factors. The current diagnostic manuals such as ICD-
11 or DSM-5 does not include neurocognitive deficits as a diagnostic criterion for 
Schizophrenia. But, DSM-5 has included extensive discussions about neurocognitive 
domain in schizophrenia. It is also suggested that, neurocognitive assessment should 
be considered as a part of routine clinical evaluation and should be universally done 
for each patient with schizophrenia. Although these impairments cannot function as 
diagnostic tools, they are strongly related to the functional outcome of the illness and, 
for that reason, have clinical value as prognostic variables, as well as for treatment 
planning. The cognitive impairments of schizophrenia have become the target of 
pharmacological and psychosocial treatment trials in the recent years. Despite the 
large number of research in this area in the last two decades, we still have to bridge 
the wide gap in the treatment of these cognitive impairments. 
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REVIEW OF LITERATURE 
 
In the late nineteenth century, Emil Kraeplin described “Dementia Praecox”, a major 
mental illness which he thought was a disease of the brain. In the early 20
th
 century, 
Eugene  Bleuler called the same illness as “Schizophrenia” which in Greek means 
“split mind”. Bleuler also thought that the disease was due to brain pathology. Thus, 
the “cognitive” domain of the illness has been recognized since the earliest days in the 
history of schizophrenia.  
 
Schizophrenia has always been considered an illness with life-long disability. The 
studies on outcome of schizophrenia has shown significant betterment with the advent 
of antipsychotics. The trend of outcome over a period of 100 years, from the late 19
th
 
century to late 20
th
 century is such that, the individuals with schizophrenia having 
good outcome, has increased from 30% to 37%. 
(50)
 
 
Earlier, it was thought that the overall improvement was largely based on clinical 
symptomatology. But, over the last few decades, cognitive functioning has been 
established as predictor of quality of life and social/ occupational functioning, 
especially in the areas of ability to sustain employment, problem- solving skills that is 
necessary for daily living activities. Thus, the emphasis is currently on improving the 
quality of life, to improve the overall outcome of the illness. 
(30) 
 
Over the years, the interest of the researchers into the neurocognition has seen many 
ups and downs. Since the birth of 21
st
 century, this particular domain of schizophrenia 
is being studied intensely. 
(22) 
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DOMAINS OF DEFICITS IN NEUROCOGNITION 
 
The assessment for neurocognitive functioning can be done using a wide range of 
tests which usually does not a test strictly one particular domain, rather one test can 
assess 2 or more domains. In schizophrenia, the most important domains of 
neurocognition are schizophrenia are working memory,attention/vigilance, verbal 
learning and memory, visual learning andmemory, reasoning and problem solving, 
speed of processing, and socialcognition.
(44,46)
 
 
A meta-analysis done in 1998 by Heinrichs and Zakzanis, included 204 studies done 
worldwide from 1980-1997, to assess the neurocognitive performance of patients 
compared with controls. The studies included assess a wide range of cognitive 
functions such as Global and selective verbal memory, non-verbal memory, motor 
performance, attention, spatial ability, executive functions, language functions, tactile 
transfer and general intelligence. This meta-analysis found a prevalence rate of 61-
78% neurocognitive deficits, which was more than that reported in previous studies. It 
also postulated that, neurocognitive deficits seen in schizophrenia can be on a 
continuum ranging from mild to profound deficits, rather than a cut-off range. It is 
also said that the cognitive functions of a particular patient depend on his premorbid 
level of functioning. Thus, the performance of schizophrenics with mild cognitive 
deficits may overlap with the performance of healthy controls, but still have 
dysfunction compared to his/her own potential. It was found that schizophrenics had 
neurocognitive deficits of large or moderate effect sizes on all the neurocognitive 
tests. 
(14) 
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The limitations of the study include, heterogeneity of the study population, use of a 
wide range of assessment tools in each study, inadequate recording of clinical and 
demographical variables. The argument of neurocognitive deficits being on a 
continuum, could mean that half of the schizophrenics may overlap with healthy 
control groups. Thus, assessing the premorbid level of functioning becomes more 
essential, which was not done in most of the studies due to various practical 
difficulties.  
 
Another meta-analysis with similar study design, done by Raquelle et al (2010) 
included 47 studies with a total of 2,204 First episode Schizophrenia patients and 
2,775 age and gender matched control groups. It analyzed 10 cognitive domains 
including language, motor skills, general cognitive ability and social cognition. 
Medium to large impairments were observed in all the cognitive domains, with 
maximal deficits seen in immediate verbal memory and processing speed. Similar to 
the previous meta-analysis, this study also put forth limitations such as limited 
information on moderator variables and significant heterogeneity across the studies. 
(17)
 
 
Various meta-analysesrevealed that, deficits in learning and memory and processing 
speed were of largest effect sizes, whereas deficits in other domains were of moderate 
to large effect sizes. Results from various methodologically sound studies showed that 
the deficits were in the range of 1 to 2 standard deviations below the healthy controls. 
(2) 
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Thus, in conclusion, severe impairment in verbal learning and memory is the most 
consistent finding across a large number of studies which is also seen to be fairly 
stable throughout the course of illness, with moderate deficits in almost all 
neurocognitive domains. 
(43)
 
 
LEARNING & MEMORY IN SCHIZOPHRENIA 
 
It has been well established that verbal learning and memory is severely affected in 
schizophrenia and this deficit also remains relatively stable throughout one‟s life(17,13). 
In the process of learning and memory, various complex neural networks are involved 
that are responsible for encoding and retrieval (recall) of information. In 
schizophrenia, both these processes are impaired, but performance relatively better on 
cued-recall. This suggests an involvement of Prefrontal cortex and medial temporal 
lobe, resulting in such deficits. The neurocognitive tests have shown that 
schizophrenia patients perform comparatively better on recognition tasks than on free-
recall tasks. 
(20) 
 
Knowledge corruption denotes holding false information with high belief, impaired 
cognitive insight and deficits in accepting the limited cognitive functioning. Patients 
with schizophrenia have been observed to have high knowledge corruption. It was 
also seen in a cross-sectional study on 71 patients that there is a significant positive 
correlation between impairment in verbal learning and memory and knowledge 
corruption in schizophrenia. Thus, impairment in verbal learning and memory can 
also affect one‟s ability to draw conclusions from the real-world experiences.(13)  
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 Hence, as a result of defective verbal learning and memory, schizophrenia patients 
may show impairment in episodic memory, drawing faulty conclusions in real-life 
situations which could in turn, predict the functional outcome. 
(20) 
 
 
ASSOCIATION WITH SOCIODEMOGRAPHIC VARIABLES 
 
Various studies have been done to analyze the relationship between demographical 
variables such as age, gender, education, geographical region, and has given 
controversial reports. 
 
In view of the differences in the neurotransmitter systems in the male and female 
brain, lot of studies have looked into the differences in the psychopathology, response 
to treatment and outcome in schizophrenia. With regards to the cognitive domain, 
studies analyzing the gender differences have showed inconsistent findings. Some 
studies have showed better performance on memory tasks in females, compared to 
males. Few other studies reported male schizophrenics have an overall better 
cognitive performance compared to females.
(7)
 One of the major limitations in these 
studies were the tools used for assessment. With the advent of MCCB (The 
MATRICS Consensus Cognitive Battery), standardized tool developed by the NIMH, 
a study was done in 112 male schizophrenics and 80 female schizophrenics along 
with a control group. The study showed that females performed better on several 
cognitive domains with a moderate effect size, except in tasks for working memory & 
reasoning and problem solving. The study also showed that largest differences 
between males and females were observed in processing speed. It was also seen that 
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processing speed, verbal learning and memory and visual learning were independently 
associated with gender.
(30)
 
The same study also showed that processing speed and verbal learning and memory 
were independently associated with age. 
(30) 
 
A cross- sectional study was done in community dwelling individuals to study the 
relationship between age and cognitive deficits in schizophrenia. 235 schizophrenia 
patients in the age range of 19-79 and 333 healthy controls in the age range of 20-81 
were included. It was found that the cognitive deficits in schizophrenia had a similar 
trajectory and rate of decline with ageing in all MCCB domains, except social 
cognition. The concludes by saying that schizophrenia can be considered as an illness 
with premature ageing wherein the cognitive deficits set in earlier in their lives, but 
remain stable without any accelerated decline in older age. This is contradictory to the 
studies that found an accelerated decline in the cognitive deficits when measured 
using other, non-MCCB assessment tools
(8)
. The study limitations included the cross-
sectional study design and less number of subjects in age group older than 70.  
 
A cross-sectional study done in 100 schizophrenia patients and 100 healthy controls 
among the Indian population revealed that older age was significantly associated with 
more decline in attention, memory and executive function, which is similar to the 
effect of ageing in the brain of a healthy individual. Among gender, male subjects had 
a poorer performance on memory tasks. Years of education was positively correlated 
with better performance on neurocognitive tests. 
(53) 
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Studies also found that, cognitive deficits were more and had rapidly declining 
trajectory in institutionalized individuals compared to community- dwelling 
individuals. The reasons for this could be, institutionalized individuals have more 
severe illness and community-dwelling individuals have a more stimulating 
environment leading to better cognition.
(8,37) 
 
Cognitive reserve is a concept developed to assess the ability of the diseased brain to 
use the cognitive networks in task performance. Over the years, cognitive reserve has 
been assessed with various indicators. Most commonly used indicators are premorbid 
IQ, years of education & occupation, leisure activities.
(51,52) 
 
A prospective, 2 years follow up study was done in 52 First episode schizophrenia 
subjects and 41 healthy age and gender matched controls. The study analyzed the 
relationship between cognitive reserve and neurocognitive functioning, which was 
measured using standardized neuropsychological tests.  It was found that subjects 
with higher cognitive reserve was significantly associated with better scores on 
working memory, executive function, verbal memory and attention. In addition to 
that, it was also concluded that cognitive reserve mediated working memory and 
executive function at baseline and the working memory at 2 years follow-up.
(3)
  This 
study gave an outline on how premorbid IQ and level of functioning can affect the 
neurocognitive functioning.  
 
 
The level of education, especially formal education of more than 15 years, has been 
found to be an independent predictor of better cognitive performances in most of the 
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studies, although few studies have also given controversial results reporting no 
significant association between education and cognitive performance. In the studies 
showing a positive correlation between education and cognition, significant 
association is seen with various cognitive domains including social cognition.
(7,26,30) 
 
A recent meta-analysis (2013) of 100 studies done worldwide analyzed the 
differences in cognitive deficits based on geographical region. The results showed no 
significant differences based on the geographical region and deficits were fairly 
consistent among all regions. It also showed that cognitive deficits in males were of 
larger effect sizes compared to females, i.e., males with schizophrenia had more 
deficits in neurocognition.
(2) 
 
Thus, among the demographical variables, years of education and premorbid level of 
functioning was seen to be significantly associated with neurocognition in 
schizophrenia. In most of the studies, evidences regarding association with gender 
was controversial and inconclusive, although a recent extensive meta-analysis showed 
more deficits in males. The cognitive decline with age in schizophrenia resembled a 
similar pattern as seen in healthy individuals, thereby concluding that schizophrenia is 
an illness of premature ageing with relative stability after the onset of cognitive 
deficits.  
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COURSE OF NEUROCOGNITIVE DEFICITS  
 
Since the advancements in research, there has been an on-going argument about 
schizophrenia being a neurodegenerative disorder or a neurodevelopmental disorder. 
Although, initially some neuroimaging studieshypothesized schizophrenia to be a 
neurodegenerative disease, in the recent years, other studies support the 
neurodevelopmental disease model, mainly owing to the stability of the cognitive 
deficits over time. In few studies, it was found that these cognitive deficits even 
improve over time.  
 
 
A 5-year follow up study was done in 26 first episode psychosis patients and the 
course of cognitive functions such as executive functions, learning and memory, 
verbal fluency, attention, working memory, processing speed and abstract reasoning 
were analyzed. The neuropsychological tests were done twice – baseline at 6 months 
and follow up at 5 years. The study revealed that all neurocognitive domains except 
working memory and processing speed were seen to be significantly improved over 
time.
(4)
  This means that, among the neurocognitive deficits, impairments in few 
domains seem to be stable over time while others improve. The results of this study, 
again support the neurodevelopmental model of schizophrenia.  
 
 
A meta-analysis of 47 studies, analyzing the neurocognitive deficits in first episode 
schizophrenia, showed that larger deficits were seen in the general cognitive ability or 
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IQ in the first episode schizophrenics compared to the premorbid level. During the 
later stages of illness, the deficits seen were comparable with that of the first episode. 
Thus, significant deterioration from the premorbid level occurs even in the first 
episode which becomes relatively stable after that.
(17)
 
 
 
A 6 month follow up prospective study in 82 first episode psychosis patients 
compared neurocognitive performance at baseline and after 6 months using CANTAB 
(Cambridge Neuropsychological Test Automated Battery). The study revealed that 
scores in working memory, processing speed and executive function seemed to 
improve over time. But, performance in verbal memory and spatial recognition 
seemed to have decreased significantly. 
(7) 
 
 
Similar results were found in a 2 years follow-up study, which was a part of the multi 
follow up Oslo study, wherein 28 schizophrenia patients were compared with 28 
healthy controls and was seen that, at 2 years follow-up assessment, there was a 
statistically significant decline in verbal learning and memory. Another interesting 
finding was that, the deficits in verbal learning and memory was greatest at the early 
phase of illness. It was also observed that there was an improvement in other 
neurocognitive domains at the 2-year follow up with significantly larger improvement 
in reasoning and problem solving and social cognition. 
(5)
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A recent meta-analysis of 376 studies showed that there was no significant association 
between duration of illness and extent of cognitive deficits.
(2)
 As discussed earlier, 
most of the studies show that, cognitive deficits tend to stabilize over time and does 
not vary with duration of the illness. 
(6,8,13,17)
 
 
 
A cross-sectional study of comparing 105 first-episode schizophrenia, 176 chronic 
schizophrenia and 300 healthy controls showed that, group with first episode 
schizophrenia had a significantly lesser deficit in working memory and social 
cognition compared to chronic schizophrenia group.
(47) 
 
 
A large, prospective, cohort study done in the Danish population wherein the 
schizophrenia patients were followed up for 10 years, showed that later age of onset 
predicted poorer performance on cognitive functions. 
(6)
 This is in contrast to the 
majority of the studies showing more cognitive deficits with early age of onset of 
illness. One explanation could be that, the mentioned study included participants with 
adulthood onset of illness, thereby having a potential limitation in the selection of 
participants. 
 
A meta-analysis of 109 studies that analyzed the effect of age of onset on cognition, 
found that patients with earlier age of onset, especially onset at less than 19 years of 
age, was significantly associated larger deficits in almost all neurocognitive domains. 
(38) 
One major limitation of the study was that, it involved very less number of studies 
on late-onset schizophrenia, which could have potentially influenced the results.  
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Most of the studies has given robust evidences for decline in verbal learning and 
memory and working memory over time, with some evidences for decline in 
processing speed. The deficits in other neurocognitive domains remain relatively 
stable irrespective of the duration of illness. Studies also suggest that cognitive 
deficits are seen even as a part of the prodrome of schizophrenia. There is also 
evidence suggesting that intervention done early in the illness has a better outcome. 
Thus, it becomes important to identify people at ultra-high risk for schizophrenia, so 
that effective treatment for the cognitive impairment can be initiated in the prodrome 
itself. 
(34) 
 
 
NEUROCOGNITION AND CLINICAL OUTCOME 
 
A Systematic review of 13 studies done from 2002- 2012, by Lepage et al (2014) 
analyzed neurocognitive deficits in remitted Vs non-remitted patients. Most of the 
studies included revealed a significant trend of poorer performance on verbal learning 
and memory in non-remitted patients as well as in non-responders to neuroleptics. 
(1) 
 
 
Although, few studies showed lower scores in visual memory, working memory, 
speed of processing among the non-remitted patients, majority of the studies failed to 
establish any significant association. 
(1) 
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Patients in the non-remitted group, obtained low scores in some of the tasks to assess 
reasoning and problem solving, although similar results were not seen in all studies. 
Thus, the association between problem solving skills and clinical improvement is 
controversial.
(1) 
 
 
This study concludes by saying that robust evidences are available for possible 
correlation between deficits in verbal learning and memory and poor clinical outcome. 
But, it does not rule out the association between deficits in other domains and clinical 
outcome. Rather, there may be association between specific neurocognitive tests and 
clinical outcome as seen with this systematic review study. Thus, future studies 
should use standardized neurocognitive batteries such as CogState Schizophrenia 
Battery or MATRICS Consensus Cognitive Battery. Though, most of the individual 
studies included in this review used definition for clinical remission given by Nancy 
Andreasen, few studies used other definitions. So, future studies should also consider 
assessing clinical remission using standard and consistent definitions. 
(1)
 
 
 
There is robust evidence for a significant association between negative symptoms and 
cognitive deficits in schizophrenia. A 3 year follow up study done in first episode 
psychosis patients, found that impairment in verbal memory, processing speed and 
executive functions was significantly associated with more severe negative symptoms 
which in turn leads to poorer clinical outcome (Addington et al.,2005).
(13)
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Another 5 years follow-up study, analyzed the association between deficits in 
neurocognitive domains and clinical outcome. It was found that deficits in working 
memory, particularly, was significantly correlated with negative symptoms. This 
working memory impairment was also seen to be stable over time, thus could result in 
long-standing residual negative symptoms. This study did not find any significant 
association between positive symptoms and neurocognitive deficits. 
(4)
 
 
 
Another study done in Indian population on first episode psychosis patients, found 
that giving cognitive retraining program significantly improved executive functioning 
which in turn improved the negative symptoms. 
(28) 
 
 
A 6 months follow-up study in first episode psychosis patients showed that, compared 
to baseline, executive functioning had significantly improved which was positively 
correlated with clinical improvement, measured with BPRS scale.
(7)
 
 
 
Hence, evidences supporting the association of cognitive domains, such as verbal 
learning and memory, executive functioning with the negative symptoms of 
schizophrenia are available in abundance, and improving these deficits should be an 
integral focus in the treatment of schizophrenia.  
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NEUROCOGNITION AND FUNCTIONAL OUTCOME 
 
Neurocognition is defined by the cognitive skills involved in carrying out 
psychological processes, and can be divided into independent but interrelated 
subdomains. Intact neurocognition is essential for social functioning 
[13,14]
. 
 
 
Functional outcome involves functioning in various areas such as self-care, 
independent living, interpersonal relations, community activities and employment. 
(1)
 
 
 
Lepage et al., (2014) noted that impairment in cognitive functioning is highly 
correlated with poor self-care and predicts poorer performance in daily routine 
activities. This finding still needs to be studied further. 
(1)
 
Independent living is another variable in functional outcome that is seen to be 
correlated with functioning in cognitive domains, especially verbal memory. Poorer 
verbal memory performance predicts a significant impairment in independent living 
ability, which in turn is seen to be negatively correlated with clinical outcome i.e., 
remission of psychotic symptoms. 
(1)
 
 
 
A randomized controlled study, done by Caplan et al., 2008, studied 2 groups of 
clinically stable homeless schizophrenics, who were randomly assigned to group 
residence or independent apartments. It concluded that clinically stable schizophrenia 
patients who were moved to a group residence, not only had better clinical outcome, 
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but also showed improvement in their performance on tasks of attention and verbal 
memory. 
(49)
 
 
 
Deficits in neurocognitive functioning is seen to be only minimally associated with 
social and interpersonal functioning, although social cognition is a robust predictor 
impairment in social functions. 
(1) 
Deficits in cognitive functions is found to be negatively correlated with community 
activities and participation. This may be due to various limitations put forth by the 
cognitive deficits. Limited executive functioning, which could lead to poor planning, 
impaired shopping skills, poor navigation abilities, poor driving skills results in 
deficits in everyday living skills and participation in the community. This is even 
more restricted, due to the financial constraints and being forced to live in an 
unfriendly neighborhood. 
(1,51,52)
 
 
 
A 2 years follow-up, prospective study which was done as a part of multi follow-up 
Oslo study, found that there was no significant association between verbal memory 
and functional outcome, measured in terms of social and role function items on 
Global Function scale. There was a positive correlation of the cognitive domains of 
attention/ vigilance and reasoning & problem solving with social and role functioning.  
A cross-sectional study analyzing the effect of various cognitive domains in real-
world behavior revealed that domains such as attention and working memory is 
directly associated with work skills, whereas executive functions was associated with 
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interpersonal skills. Processing speed was seen to be significantly related to both 
social and occupational competence.
(18) 
 
 
Among the various domains of neurocognitive deficits, a 5 year follow up study in 
first episode psychosis subjects, found a significant association between working 
memory deficits and functional outcome as measured by FAST (Functional 
Assessment Short Test)
(4)
. This study also suggests that, this poor functional outcome 
may be due to the negative symptoms of schizophrenia, which were also significantly 
associated with working memory deficits.  
 
 
A meta-analysis of 20 studies studied the relationship of neurocognitive domains with 
subjective measures of Quality Of Life (QOL) and objective measures of Quality Of 
Life. It showed that all neurocognitive domains were positively correlated with 
objective QOL. In contrary, almost all neurocognitive domains were either not 
significantly associated or negatively correlated with subjective QOL. Only verbal 
fluency was positively correlate with subjective QOL.  This study emphasizes on the 
significant differences in the association of neurocognition and subjective/ objective 
measures of QOL and thereby the need to address the same in treatment implications.  
 
 
Thus, the most important predictors of functional outcome are attention, verbal 
learning and memory and executive function. Social cognition is strongly associated 
with social/ community functioning.  
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GENETICS OF NEUROCOGNITION IN SCHIZOPHRENIA 
Recently, various researches are done to study the relationship between neuro-
biological markers or genetic loading and neurocognition in schizophrenia. This has 
also given rise to arguments that neurocognitive impairment should be considered as a 
genotype/ endophenotype in schizophrenia.  
 
Studies have established that neurocognitive deficits in schizophrenia are highly 
heritable. But, among the various domains of deficits, which domains are affected due 
to genetic loading is still under research. Few studies have showed that first degree 
relatives of schizophrenia patients have deficits in neurocognitive functioning with a 
small to medium effect size. Of these, deficits in IQ and working memory are found 
to be highly due to genetic loading.  
 
A cross –sectional study done on 28 patients and 129 unaffected biological parents 
compared the neurocognitive deficits with matched control group. It was found that 
both the unaffected parents of a schizophrenia patient showed medium effect sized 
deficits in attention, memory and executive function. Among the unaffected parents, 
the most likely carriers showed larger impairment in attention and executive function, 
thereby supporting the role of genetic loading in the deficits. 
(24)
 
 
 
An Indian study of a small sample size analyzed the neurocognitive functioning of 
schizophrenia patients, compared with their unaffected siblings and healthy controls. 
The unaffected siblings were noted to perform poorly on verbal learning and memory 
compared to healthy controls. Although, this study showed significant difference in 
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only verbal learning and memory, various other studies have found that the unaffected 
siblings show impairments also in other domains such as working memory and 
executive functions with modest effect sizes. 
(25) 
 
Another Indian Study analyzed the relationship between P300 and neurocognition in 
patients and unaffected siblings compared to healthy controls. It was found that, both 
P300 and neurocognitive deficits fall on a continuum, wherein the healthy controls are 
on an extreme, schizophrenia patients on another extreme with the unaffected 
biological relatives occupying an intermediate position.
(54) 
 
 
Oxidative stress is postulated as a cause in many psychiatric disorders; most of the 
studies have found oxidative stress to be associated especially with Schizophrenia.  
Oxidative stress markers such as Glutathione(GSH), Nitric oxide(NO), Superoxide 
dismutase(SOD), Glutathione peroxidase, BDNF, Neurotropin 4/5 (NT4/5) are some 
examples of the biomarkers that are being extensively studied. A large number of 
studies have found a positive correlation between oxidative stress biomarkers and 
neurocognitive deficits; evidences are coming up for association with high levels of 
Malondialdehyde, Nitric oxide and low levels of Glutathione, Superoxide dismutase.  
Martinez-Cengotitabengoa and colleagues were the first to investigate the potential 
relationship between the levels of oxidative stress and neurocognition in 
schizophrenia, and found a significant correlation between GSH and executive 
function.  
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Gonzalez-Liencres et al., in 2014, studied the association of oxidative stress 
biomarkers with neurocognition and social cognition in 50 clinically stable 
schizophrenia patients. They found a statistically significant positive correlation 
between NT4/5 levels and executive function and visual attention. Interestingly, no 
significant correlation of biomarkers was found with social cognition.
(16)
 
 
 
Thus, from the available research, one can say that due to genetic loading, there is an 
innate vulnerability to develop schizophrenia and when environmental factors exploit 
that vulnerability, the illness sets in.  
 
 
ASSESSMENT TOOLS 
 
One of the major limitation in the studies on neurocognition in schizophrenia is the 
use of a long list various assessment tools, which makes comparisons between 
individual studies difficult. The tools can be an extensive list of tasks testing various 
domains, multiple tasks testing one or two specific inter-related domains, composite 
tool with a few important tasks to assess the general neurocognitive functioning. The 
choice of an assessment tool should be based on the purpose of the study. For 
clinician‟s use, an easily administered tool that is less time consuming should be 
preferred, such as SCoRS, UPSA, RBANS, BACS, BCA. Among these, UPSA, 
SCoRS and BCA also assess the functional outcome. For research purposes, extensive 
batteries like WAIS, WMS, MCCB can be used. In many studies done in the past, 
RBANS, BACS, WAIS, WMS, a list of specific tasks to assess the specific domain 
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have been used. Recently, NIMH funded MATRICS initiative has come up with 
MCCB, which is the most commonly used tool in the recent years of research. 
(35) 
 
 
[SCoRS = Scale for Cognition in Schizophrenia; UPSA = University of California 
Performance-Based Skills Assessment; RBANS = Repeatable Battery for Assessment 
of Neuropsychological Status ; BACS = Brief Assessment of Cognition in 
Schizophrenia ; BCA = Brief Cognitive Assessment ; WAIS = Wechsler Adult 
Intelligence Scale ; WMS = Wechsler Memory Scale ; MCCB = MATRICS 
Consensus Cognitive Battery] 
 
 
IMPLICATIONS IN TREATMENT 
 
Traditionally, schizophrenia is treated with antipsychotic medications and it has been 
well established that, it significantly improves the clinical outcome. When the 
cognitive deficits are considered, the role of antipsychotic treatment is yet to be 
explored. Studies have found that, both, patients with antipsychotic treatment history 
and drug naïve patients, displayed similar profile of neurocognitive deficits, which 
suggest that, antipsychotics may not improve the cognitive deficits. 
(43)
 
 
The CATIE trial, which is a double blind, randomized controlled trial, analyzed the 
neurocognition in 817 patients, who were randomized to 4 second generation 
antipsychotics such as risperidone, olanzapine, quetiapine, ziprasidone and first 
generation antipsychotic Perphenazine. At 2 months following treatment, minimal 
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improvement in cognitive deficits were noted, with no statistically significant 
difference between the drugs. But, the study showed only a negligible effect size and 
also had significant biases. 
(48)
 
 
 
Most of the studies analyzing the effect of second generation antipsychotic treatment 
on cognition showed only small effect sizes, and also had lot of methodological 
issues. 
(43) 
Studies comparing first generation and second generation antipsychotic 
medications, were mostly either funded by sponsor with a conflict of interest, or used 
inappropriate doses of drugs to compare. One thought to be considered while 
choosing antipsychotic medications is that, first generation antipsychotics, due to its 
high propensity for extra pyramidal side effects, will most often require an 
anticholinergic drug, which can worsen the cognitive impairment. 
(43)
 
 
 
A randomized double blinded placebo-controlled, phase II study was done in chronic 
schizophrenia patients wherein, the effect of Recombinant Human Erythropoietin was 
analyzed on cognition, based on the evidence on neurotrophic effects of rhEPO. The 
neurocognitive functions were assessed at various points of time over 12 weeks. The 
study showed that both rhEPO group and placebo group showed some improvement 
in all cognitive domains with a slightly more, statistically significant improvement in 
the rhEPO group, which was independent of the effect on other symptom domains of 
schizophrenia. But, the study had limitations such as, the sample size was very small, 
duration of treatment was only 3 months, and the effect sizes were also small. 
(10) 
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There is preliminary evidence suggesting the beneficial effects of adjuvant estrogen in 
improving the cognitive functions in schizophrenia, especially verbal memory. This is 
based on the concept and evidence that estrogen in the brain promotes neuronal 
growth and neuronal plasticity thereby acting as a neuroprotective agent. But, due to 
the risk of various adverse effects in the long-term use of estrogen, this area is still 
under-explored. A double blinded, placebo controlled RCT done over 13 weeks with a 
cross-over study design, analyzed the effect of adjuvant Raloxifene, which is a 
selective second-generation estrogen receptor modulator when given for 13 weeks. 
The results showed significant improvement in attention and processing speed at 13
th
 
week in the Raloxifene group. But, the study was not devoid of limitations, in its 
study design, selection of patients and the short duration of treatment. 
(36) 
 
 
There is a large number of studies published in the recent years, supporting the use of 
glutamatergic agents after the piling evidence for glutamate hypothesis in 
schizophrenia.  Drugs acting on NMDAR, which are currently in phase II or III trials 
include Glycine site agonists such as Glycine and D-serine, Glycine reuptake 
inhibitors like bitopertin, Metabotropic type 5 receptor agonists, α 7 nicotinic 
agonists. But, the largest of the effect sizes from these studies were only 0.3, which is 
a small effect size statistically. Other drugs that target 5HT-A1 and 5HT-A7 
(Lurasidone) which are serotonergic receptors are also being studied, but with 
inconclusive evidences supporting these. Cognitive enhancers such as Donepezil or 
Modafinil are not found to be useful. 
(55) 
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There have been many studies done in the western countries looking at the effect of 
cognitive retraining or cognitive remediation therapy on the cognitive deficits seen on 
schizophrenia, targeting specific neurocognitive domains. The studies revealed mixed 
results with few studies showing positive results including improvement in cognitive 
deficits, negative symptoms and thereby improving the functional outcome. It was 
also seen that cognitive retraining given in the early phase of illness gave more 
benefits. Multiple meta-analyses done in this area showed robust evidences with a 
medium effect size supporting cognitive retraining 
(55)
. But, there were lot of 
limitations in putting it to practice, which included high cost of treatment, frequent 
hospital visits and thus, resulting in poor adherence to therapy. It was also seen that, 
though some improvement was seen in the neurocognitive tests, it was not 
consistently correlated with improvement in functional outcome i.e., the improvement 
in the neurocognitive tests were not translated to improvement in social/ occupational 
functions in real life.  
 
 
In Indian set-up, the high cost of treatment and limited availability of training 
personnel, becomes very important factors that limits the adherence and effective 
delivery of cognitive remediation therapy. Thus, home-based cognitive retraining 
programs started gaining popularity. A randomized controlled study to examine the 
effectiveness of the same, was done in 45 first episode psychosis patients, where 
patients were randomized to treatment as usual group and adjuvant cognitive 
remediation training. The training was delivered under the supervision of a care-giver 
daily at home for 2 months and the tasks were graded based on difficulty. At the end 
of 2 months, the cognitive retraining group showed significant improvement in 
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executive functions such as divided attention, planning, concept formation and set-
shifting ability, which sustained till 6 months. The study had some serious limitations, 
small sample size, significant drop out, no blinding for the rater for assessment. 
(28) 
 
 
Although lot of research has been done on treatment for neurocognitive dysfunction, 
no conclusive evidence has come up for any of the treatment modalities. Thus, NIMH 
sponsored an initiative to bring the researchers, clinicians, Pharmaceutical companies 
together to develop standardized tools to assess and drug targets that would improve 
cognition in schizophrenia. MATRICS – Measurement and Treatment Research to 
Improve Cognition in Schizophrenia was the first in that initiative which came up the 
standardized tool MCCB (The MATRICS Consensus Cognitive Battery) assessing 7 
neurocognitive domains that are to be the main focus in schizophrenia
(44)
. Due to 
certain limitations in MATRICS, another initiative was developed – CNTRICS i.e., 
The Cognitive Neuroscience Treatment Research to Improve Cognition in 
Schizophrenia 
(46)
. In the recent years, CNTRICS has been conducting meetings and 
research in developing imaging biomarkers, such as,  fMRI, EEG, EMG and TMS 
which can be used in identifying targets and drug developments. 
(23,46) 
 
 
Currently, we stand at a place where we don‟t have conclusive evidence supporting 
pharmacotherapy for neurocognitive dysfunction seen in schizophrenia. Cognitive 
remediation, especially when given in the early phase of illness, appears to have 
enough evidence to support its use, but it comes with a lot of limitations too.  
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RATIONALE FOR THE STUDY 
 
With the up-roar in the neurocognition in schizophrenia in the recent year, many 
studies have been done worldwide regarding the cognitive deficits and functional 
outcome in schizophrenia. As we all know, the overall outcome of schizophrenia in 
developing countries like India is not the same as that of western countries. To our 
knowledge, there are no Indian studies that directly correlates thecognitive deficits 
with the disability in schizophrenia among Indian population. And the few studies on 
cognitive deficits among the Indian population have used tools that are developed in 
the western countries, which may have cultural variations and makes it difficult to use 
those tools without modifications. Thus, studies looking into both neurocognition and 
the functional outcome in our population using validated tools specifically developed 
in our cultural context may render a better knowledge regarding cognitive deficits and 
disability in the Indian schizophrenia patients.  
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AIM  
 
 To assess the neurocognitive functions among patients with schizophrenia and 
compare with healthy controls. 
 
 
 
PRIMARY OBJECTIVE 
 
To compare the neurocognitive functions of clinically stable Schizophrenia patients 
with that of healthy age and gender matched controls. 
 
SECONDARY OBJECTIVES 
 
1. To compare the neurocognitive functioning between patients with less than 2 
years duration of illness and more than 2 years duration of illness among the 
Schizophrenia group. 
 
 
2. To correlate the neurocognitive functions and disability among clinically 
stable schizophrenia patients. 
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METHODOLOGY 
 
STUDY DESIGN 
 
It is a Cross-sectional study design. Convenient sampling was done for recruitment of 
participants. The total number of participants recruited is 40, among which 20 were 
clinically stable schizophrenia patients and 20 were age and gender matched healthy 
controls. The study was conducted at PSG hospital, Peelamedu.  The study was 
conducted from July 2017 to August 2018. The assessment  
 
 
STUDY PARTICIPANTS 
 
The participants were recruited from Out Patient Services in the Department of 
Psychiatry at PSG Institute of Medical Sciences and Research. The Schizophrenia 
group consisted of patients visiting the out-patient department during their routine 
clinical visit.  
 
 
The healthy control group consisted of participants who were relatives of in-patients 
in our hospital or hospital staff. The control group was matched for age and gender 
with the Schizophrenia group. 
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INCLUSION CRITERIA FOR PATIENTS 
 
• Age of 18 to 60 years 
• Patients who qualify for the diagnosis of Schizophrenia according to ICD 10 
criteria, currently stable 
• Patients without any other psychiatric diagnoses as per MINI  
• Patients who can read English/ Tamil  
• Remission criteria: PANSS (Positive and Negative Syndrome Scale) score of  less 
than or equal to 3 each, on items 1-3 of positive subscale, on items 1,4 & 6 of 
negative subscale, on items 5 & 9 of general psychopathology subscale, in the 
previous 3 months. 
 
 
EXCLUSION CRITERIA FOR PATIENTS 
 
• Patients with significant comorbid organic conditions 
• Substance dependence except nicotine dependence 
• Low vision, color blindness 
• Patients with significant movement disorder 
• Mental retardation 
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INCLUSION CRITERIA FOR CONTROLS 
 
• Age of 18 to 60 years  
• Participants without any psychiatric diagnoses as per MINI  
• Participants who can read English/ Tamil  
• Participants with normal vision, without color blindness  
 
EXCLUSION CRITERIA FOR CONTROLS 
• Participants with significant comorbid organic condition 
• Substance dependence except nicotine dependence 
• Low vision, color blindness 
• Mental retardation 
 
Participants who fulfilled the inclusion & exclusion criteria and gave written informed 
consent to participate in the study were recruited.  
 
TOOLS TO BE USED 
PANSS 
The Positive and Negative Syndrome Scale (Stanley Kay, Lewis Opler, and Abraham 
Fiszbein, 1987) is a scale to measure the symptom severity in Schizophrenia. It has 30 
items, out of which 7 constitutes the Positive symptoms scale, 7 constitutes Negative 
symptoms scale and the remaining 16 constitutes the General Psychopathology scale. 
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Each item is scored on a scale of 1 to 7, with 1 being absent and 7 being extreme. In 
our study, this scale was used to assess the remission in schizophrenia patients, 
according to the Remission Criteria given by Nancy Andreasen et al. (2005). As per 
the criteria, scores less than or equal to 3 on selected items of the PANSS scale is 
required for remission. 
(11) 
 
 
The items include:  
- Delusions (P1), Conceptual disorganization (P2) and Hallucinatory behavior (P3) of 
the Positive symptom subscale 
- Blunted affect (N1), Social withdrawal (N4) and Lack of Spontaneity (N6) of the 
Negative symptom subscale 
- Mannerism / Posturing (G5) and Unusual thought content (G9) of the General 
Psychopathology subscale 
 
 
The PANSS rating was done by the researcher on all the schizophrenia patients 
recruited for the study. Fulfilling the above criteria for the last 3 months before 
participation in the study is considered as remission / clinically stable schizophrenia.  
 
 
M.I.N.I. 
 
The Mini International Neuropsychiatric Interview (M.I.N.I. 5.0) is a brief structured 
interview for the major Axis I psychiatric disorders in DSM-IV and ICD-10. It is a 
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clinical interview with very precise questions about psychological problems which 
require a yes or no answer. The M.I.N.I. is divided into modules, each corresponding 
to a diagnostic category.  At the beginning of each diagnostic module screening 
question(s) corresponding to the main criteria of the disorder are given.  At the end of 
each module, diagnostic box(es) permit the clinician to indicate whether diagnostic 
criteria are met. All questions must be rated based on the yes/no answer.  
 
Both Schizophrenia patient group and the healthy control group were required to 
undergo screening with M.I.N.I to rule out any major psychiatric disorders. M.I.N.I. 
was applied on both schizophrenia patient group and healthy control group by the 
researcher. 
 
 
NIMHANS NEUROPSYCHOLOGICAL BATTERY 
 
This Neuropsychological Battery to assess the neurocognitive functions was 
developed by the National Institute of Mental Health and Neuro Sciences (Rao, 
Subbakrishna, Gopukumar, 2004). We decided to use this battery, rather than any 
other Internationally used neuropsychological assessment tool, as those tools 
developed in western countries cannot be used in our Indian population without slight 
modifications in the tests; alsothe normative data for scoring may not be valid in an 
Indian context. Thus, the NIMHANS Neuropsychological Battery was developed with 
normative data for our population and validated for use internationally, which will be 
used for our study. The tool has a specificity of about 85%.  
(12) 
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The battery has a list of 19 tests to assess seven cognitive domains such as speed, 
attention, executive functions, comprehension, verbal learning and memory, visuo-
spatial construction and visual learning and memory. 
 
For our study, we selected 8 tests that assessed five neurocognitive domains – speed, 
attention, executive function, verbal learning and memory, visual learning and 
memory and visuo-spatial construction.  
 
S.No COGNITIVE DOMAIN FUNCTION NAME OF THE TEST 
1. Speed of Processing Mental speed Digit symbol substitution 
test 
2. Attention Sustained attention Digit vigilance test 
3. Executive functions Verbal fluency Controlled Oral Word 
Association Test 
(COWA)  
4.  Category fluency Animal naming test 
5.  Working memory Verbal N back test 
6.  Response inhibition Stroop test 
7. Learning and memory Verbal Auditory Verbal 
Learning test 
8. Visuo-spatial construction 
Visual learning & memory 
Visual  Complex figure test 
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DIGIT SYMBOL SUBSTITUTION TEST 
 
This assesses visuo-motor coordination, motor persistence, sustained attention and 
speed of processing. It consists of numbers 1 to 9 in 100 squares arranged randomly in 
4 rows in a sheet of paper. Each number is assigned a symbol, which is given at the 
top of the page. The participant is required write the respective symbols under each 
digit. The instructions are explained by the researcher and the first ten squares are 
done as practice with the researcher‟s help. After that, the participant is asked to do on 
their own by filling the symbols row-wise and to do as fast as possible. The researcher 
notes down the time taken to finish the task and the errors made are also noted down.  
 
 
DIGIT VIGILANCE TEST 
 
This is a test for sustained attention. The test consists of a sheet of randomly arranged 
digits from 1-9. The sheet has 50 rows and each row has 30 digits which are closely 
placed to each other. The researcher instructs the participant to mark two target digits 
(1 & 5) by making a „/‟ symbol over the digits. The first row can be done for practice 
with the resesarcher‟s help. The participant is asked to work row by row, and to do as 
fast as possible without missing the target digits or mark non-target digits. After the 
task is completed, the total time taken by the participant is noted. Both omission and 
commission type of errors are also noted down and counted how many are made in 
total. 
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CONTROLLED ORAL WORD ASSOCIATION TEST (COWA) 
 
It is a test of phonemic fluency. It measures one‟s ability to generate words based on 
phonetic similarity. The researcher is to instruct the participants to generate as many 
new words as possible in 60 seconds, that starts with consonants F, A and S. For non-
English speaking participants in India, consonants such as „Ka‟, „Pa‟, „Ma‟ are given 
and asked to generate words in their mother tongue. While using consonants from 
their mother tongue, the various inflections of the same letter can also be used to 
generate new words – for example, Ka, Kaa, Ki, Kee, Ku, Ke, etc. Before starting the 
test, a practice test can be done using another consonant which is not used for the 
actual test. The participant is instructed not to generate proper nouns such as names of 
person or place, names of numbers or series of words by changing only the suffix (eg., 
fast, faster, fastest). The three consonants are given one after another, with a short 
pause after each completing each consonant. The researcher notes down all the words 
generated, counts the number of acceptable words for each consonant and then 
calculate the average number of new words generated over the 3 consonants.  
 
ANIMAL NAMING TEST 
This is a test for category fluency, which is a form of verbal fluency. It measures the 
ability of a person to generate words belonging to a particular semantic category. In 
this test, the participant is given 60 seconds and asked to generate the names of 
animals, but not names of fish, birds, insects or snakes. The participant is asked not to 
repeat the same name twice. The animal names generated are noted down and the 
total number of new words generated forms the score.  
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VERBAL N BACK TEST 
It is a test of externally guided working memory. It has 2 versions – Verbal 1 back 
and Verbal 2 back tests.  
 
 
VERBAL 1 BACK TEST 
This test involves verbal storage and rehearsal. It assesses the verbal working 
memory. The test comprises of a list of 30 randomly selected and arranged consonants 
which are common to multiple Indian languages. Of these, nine consonants are 
repeated consecutively in the list. The participant is instructed to tap once when 
he/she hears the same consonant being repeated consecutively. A practice test is given 
by the researcher, consisting of 4 consonants with 1 consonant being repeated 
consecutively. While presenting the list of consonants, the number of correct and 
incorrect responses are noted down. The number of correct responses is the number of 
hits. The number of incorrect responses or missing to make a correct response is the 
number of errors – commission and omission errors.  
 
 
VERBAL 2 BACK TEST 
This test requires verbal storage and rehearsal and manipulation of information. It 
tests the central executive working memory. Similar to Verbal 1 back test, this test 
comprises of a different set of 30 randomly selected and arranged consonants 
common to multiple Indian languages. Of these, nine consonantly are repeated 
consecutively with an intervening consonant between the consecutive repetition (eg., 
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La-Kha-La). The participant is instructed to tap when he/she hears the same 
consonant consecutively with an intervening consonant. A practice test is given by the 
researcher with list 4 consonants, wherein 1 consonant is repeated consecutively. The 
test list of consonants is then presented and the number of correct responses, omission 
and commission errors are noted down. The number of correct responses is the total 
number of hits.  
 
 
STROOP TEST 
 
This is a test for response inhibition, which is an executive function. It consists of a 
sheet of paper with a list of randomly arranged words such as “RED”, “GREEN”, 
“BLUE” and “YELLOW” printed in colored text and in capital letters. The color of 
the text occasionally corresponds to the word printed. First, the participant is 
instructed to read the words in the list column-wise. Then, the participant is instructed 
to name the color of the text from the same list and he/she can repeat the response in 
case of a wrong response. A practice test can be given for first 5 words. The time 
taken for both tasks is noted down. The time taken to name the color of the text will 
be more than the time taken to read the words. The difference between the two is the 
“Stroop effect”. The Stroop effect in seconds is calculated.  
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AUDITORY VERBAL LEARNING TEST 
 
This is a test for verbal learning and memory. It assesses the capacity to learn and 
remember verbal material. This test is an adaptation of Rey‟s Auditory Verbal 
Learning Test (AVLT) and is available in translated versions in 4 Indian languages – 
Hindi, Tamil, Telugu and Kannada. The test consists of two separate lists of 15 words 
each and these words can be names of familiar objects like vehicles, body parts, tools 
and animals. At first, list A consisting of 15 words is presented to the participant and 
after completion of the list, he/she is asked to recall as many words as possible. 
Similarly, five consecutive trials are given and the number of words recalled is noted 
down for each trial. After the five trials, list B consisting of a different set of 15 words 
is presented to the participant and he/she is asked to recall words from list B 
immediately. After this interference, immediate recall of list A is done. Twenty 
minutes later, during which time, others non-verbal tasks can be done, the delayed 
recall of list A is assessed. After the delayed recall, a list of 30 words, out of which 15 
are from list A is presented to the participant. Whenever a word from list A is 
presented, the participant is asked to tap on the table. This tests the recognition. The 
total number of correct hits, omission and commission errors are noted down.  
 
Learning score comprises the number of words recalled correctly in each of the first 
five trials and the total number of words recalled over the five trials. Memory score 
comprises the number of words recalled correctly in the immediate recall of list A and 
B, delayed recall of list A and recognition trial. Long Term Percent Retention (LTPR) 
is the percentage score calculated by the formula –  
                       (Delayed recall score/Trial 5 score) X 100 
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COMPLEX FIGURE TEST (Rey’s) 
 
 
This is a test for visuo-constructive ability and visual learning and memory. The test 
consists of three trials – the copying trial, the immediate recall trial and the delayed 
recall trial. It is done using a complex, abstract design with multiple subcomponents, 
which is presented to the participant only once during the copying trial. First, the 
participant is asked to copy this complex figure on a piece of paper free-hand. An 
eraser can be used. This tests the visuo-constructive ability. After a three minutes 
interval during which time, other simple tasks from the battery can be done, the 
immediate recall is assessed by asking the participant to reproduce the figure as 
accurately as possible. Then, following 30 minutes interval, during which time other 
verbal tasks are to be done, delayed recall is assessed by asking the participant to 
reproduce the figure as accurately as possible.  
 
Each of the three trials is scored depending upon the accuracy of the figure and 
placement of the component parts of the figure.  
 
SCORING OF NEUROPSYCHOLOGICAL TESTS 
 
After the completion of all tasks, the individual scores and the number of errors from 
each test is noted down. These scores are matched against the normative data table 
given in the battery. The percentile scores are then obtained based on the age, gender 
and educational status of the participant.  
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In our study, the researcher took training on how to perform the neuropsychological 
tests needed for our study, from a Clinical Psychologist who holds a Ph.D. in Clinical 
Psychology. Under the supervision of the Clinical Psychologist, neuropsychological 
assessment was done by the researcher for five normal volunteers, before the 
initiation of the study. For the study, the neuropsychological assessment and scoring 
was done by the researcher.  
 
 
IDEAS 
 
The Indian Disability Evaluation and Assessement Scale (IDEAS) was developed by 
the Rehabilitation Committee of the Indian Psychiatric Society in the year 2000. It is a 
scale for assessing and quantifying disability in patients with mental illnesses. This 
scale is validated and best suited for using in the Indian population.  
 
The scale consists of 4 domains – Self-care, Interpersonal activities, Communication 
& Understanding and Work. The scale also gives a list of guiding questions for 
assessing disability in each domain. Each domain is scored on a scale of 0 to 4 
wherein, 0 means no disability and 4 means profound disability. The sum of the 
scores on all the 4 domains constitutes the total score.  
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Depending on the duration of illness, an additional score of 1 to 4 has to be added, 
where 4 is for duration of illness more than 10 years. This is the „Duration of illness‟ 
score. 
 
The global disability score is the sum of Total score and Duration of illness score. 
This can range from 0 to 20. A score of 0 means No disability and 20 means profound 
disability. Higher the score, more is the disability.  
 
A global disability percentage is also given based on this Global disability score.  
 
Global score     :       Global Disability Percentage Score 
0                        :        0%                 = No disability 
1 to 6                 : < 40 %          = Mild disability 
7 to 13               :        40 to 70 %    = Moderate disability 
14 to 19             :         71 to 99 %   = Severe disability 
20                      :         100%           = Profound disability 
 
According to this scale, a global disability percentage of 40% and above is the cut-off 
to be eligible for welfare measures given by the Government of India.  
 
All the participants in the Schizophrenia group were scored on the IDEAS and Global 
Disability Percentage score was calculated. The scoring was done by the Primary 
Investigator based on the interview, reports from the care-giver and medical records 
from the patient‟s hospital file.  
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The tools were applied for the schizophrenia group and control group as follows: 
 
SCHIZOPHRENIA GROUP    CONTROL GROUP 
              PANSS                                                                 M.I.N.I. 
        
             M.I.N.I.                                                                       
        
NIMHANS Neuropsychological Battery         NIMHANS Neuropsychological Battery 
  
    IDEAS 
 
Ethical approval was obtained for the study from the Institutional Human Ethics 
Committee of PSG Institute of Medical Sciences and Research.  
 
 
SAMPLE SIZE ESTIMATION 
Considering the similar previous studies and number of patients attending our OPD 
from previous statistics, we decided to have a sample of twenty schizophrenia patients 
and twenty age and gender matched healthy controls. 
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STATISTICAL ANALYSIS 
All calculations were performed using IBM SPSS Statistics (version 
20.0 SPSS Inc., Chicago, IL, USA). 
 
In the test of normality as assessed by Shapiro-Wilk test, the normalityof distribution 
of variables under interest is tested, by comparing the correlation of the data 
(variables of interest) with the corresponding normal scores. The pvalues of most of 
the variables are >0.05, which indicates that thesevariables are normally distributed 
across the cases & controls and thusparametric test were used for analysis. 
 
 
Outlier is the extreme value which does not correlate with other value in the variable.  
Box-and-whisker plots graph depicted that the majority of the scores of 
neuropsychological tests have no outlier observation/negligible amount of outlier 
observation.  Hence, further analysis was carried out.  
 
 
In both groups (schizophrenia patients and healthy controls), socio demographic 
variables, neuropsychological test scores, functioning scores were assessedusing 
relative and absolute frequencies, means, and standard deviations, whichever deemed 
appropriate. 
 
 
Comparison between the schizophrenia group and control group, and within the 
schizophrenia group (<2 years Vs >2 years duration of illness) regarding 
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neuropsychological test scores and sub-group analyses based on age, gender and 
educational status were done using Independent sample t test (for discrete variables) 
and ANOVA (Analysis of Variance) test (for continuous variables). The level of 
statistical significance was set at 5% i.e., p<0.05. 
 
For analysis of correlation between the disability assessment scores and 
neuropsychological test scores, Pearson correlation analysis was used with statistical 
significance set at p<0.05. 
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RESULTS 
SECTION I: SOCIODEMOGRAPHIC VARIABLES 
TABLE 1.1: DEMOGRAPHIC DETAILS OF SCHIZOPHRENIA PATIENT 
GROUP AND HEALTHY CONTROL GROUP 
 
Socio-Demographic details Schizophrenia group Control group 
Gender   
Male 9 (45) 9 (45) 
Female 11 (55) 11 (55) 
Total 20 (100) 20 (100) 
Age group   
18-30 8 (40) 8 (40) 
31-50 10 (50) 10 (50) 
51-65 2 (10) 2 (10) 
Total 20 (100) 20 (100) 
Education level   
School level 12 (60) 9 (45) 
College level 8 (40) 11 (55) 
Total 20 (100) 20 (100) 
Marital status   
Married 10 (50) 14 (70) 
Unmarried 8 (40) 6 (30) 
Separated 2 (10) - 
Total 20 (100) 20 (100) 
Occupation Status   
Working 7 (35) 15 (75) 
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Not working 13 (65) 5 (25) 
Total  20 (100) 20 (100) 
Duration of illness   
Patients with duration of illness                  
<2 years 
8 (40) - 
Patients with duration of illness >2 
years 
12 (60) - 
Total 20 (100) - 
  
 
Table 1 presents the demographic details of the 2 groups - schizophrenia patients 
group and healthy controls group.  The total number of participants of the study are 
40. Among the 40 participants, 20 are clinically stable schizophrenia patients and 20 
age and gender matched healthy controls.  
 
 
The mean age of the participants is 35.5 years, half of the total number of participants 
aged 31-50 years, followed by 40% aged between 18-30 years and only 10% aged 
between 51-65 years.  
 
 
There were almost equal number of male and female participants, with females being 
55% and males being 45%. 
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In schizophrenia group, 50% of the participants were married and 50% were 
unmarried or separated. In the control group, 70% of participants were married.  
 
 
The majority of participants in the schizophrenia group (60%) completed school level 
education while the majority in the control group has completed college level 
education (55%). 
Among the schizophrenia patients, 60% have duration of illness more than 2 years 
with mean duration of as 10.3 years, whereas 40% have duration of illness less than 2 
years with mean duration of 14.25 months.  
 
In the schizophrenia patients group, the mean duration of untreated psychosis i.e., 
before initiation of treatment is 19.7 months.  
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SECTION II: OUTLIER IDENTIFICATION IN THE DATA OF 
NEUROPSYCHOLOGICAL TEST SCORES 
 
FIGURE I: BOX-AND-WHISKER PLOT GRAPH FOR OUTLIER 
IDENTIFICATION 
 
 The above figure depicts that the majority of data of the neuropsychological 
test scores have no outlier observation/negligible amount of outlier observation.   
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SECTION III: COMPARISON OF SCHIZOPHRENIA PATIENTS AND 
HEALTHY CONTROL GROUP 
 
TABLE 3.1 - DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN SCHIZOPHRENIA PATIENT GROUP AND HEALTHY 
CONTROL GROUP 
Neuropsychological tests 
Schizophrenia  Controls t-Value P-value 
Mean±Sd 
DST total time 32.65±17.62 66.95±7.61 -7.992 0.001** 
DVT total time 24.20±10.49 57.75±9.54 -10.580 0.001** 
DVT errors 28.45±18.52 22.90±9.88 1.183 0.247 
COWA Avg. new words 34.20±20.23 64.00±13.92 -5.428 0.001** 
Animal naming Total new words 31.45±16.87 61.75±14.89 -6.021 0.001** 
Verbal N back- Hits 36.50±20.72 54.75±13.90 -3.271 0.002** 
Verbal N back - Errors 45.05±24.94 59.35±27.28 -1.730 0.092 
Stroop effect 45.05±23.80 73.95±7.07 
-5.206 0.001** 
AVLT - Memory score 18.90±8.85 62.00±17.04 -10.036 0.001** 
AVLT - Learning score 14.90±7.40 57.00±16.09 -10.629 0.001** 
AVLT - LTPR 14.50±11.64 55.25±16.02 -9.204 0.001** 
AVLT - Misses 20.05±10.16 34.55±24.41 -2.452 0.021* 
AVLT - False alarms 80.90±34.32 88.85±23.01 -0.860 0.396 
CFT 21.30±10.94 55.50±14.95 -8.258 0.001** 
**P<0.01; *P<0.05 
Table 8.2 shows that, on comparing the neuropsychological test scores between the 
schizophrenia group and healthy control group, the schizophrenia group obtained 
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statistically significant (p<0.05) poorer scores than the control group in Digit 
Substitution test (DST) total time, Digit Vigilance Test (DVT) total time, Controlled 
Oral Word Association (COWA) test- Average New Words, Animal naming test – 
Total New Words, Verbal N back Hits, Stroop effect, Auditory Verbal Learning Test 
(AVLT) Memory score, AVLT Learning score, AVLT Long Term Percent Retention 
(AVLT-LTPR), AVLT Misses and Complex Figure Test (CFT). The means and 
standard deviations of the scores obtained by the two groups are given in the table 
above. 
 
There was no statistically significant difference between the scores of the two groups 
in Digit Vigilance Test errors, Verbal N Back Errors and Auditory Verbal Learning 
Test False alarms (p>0.05) 
FIGURE 2 : MEAN SCORES CHART FOR THE NEUROPSYCHOLOGICAL 
TESTS’ SCORES IN SCHIZOPHRENIA PATIENTS GROUP AND HEALTHY 
CONTROL GROUP 
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TABLE 3.2: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN MALE SCHIZOPHRENIA GROUP AND MALE CONTROL 
GROUP 
Neuropsychological tests 
Male 
Schizophrenia 
group  
Male 
Control 
t-Value P-value 
Mean±Sd 
DST total time 33.78±21.17 69.11±7.67 -4.707 0.001** 
DVT total time 24.33±13.69 53.00±7.65 -5.483 0.001** 
DVT errors 29.89±21.91 24.89±10.41 0.618 0.545 
COWA Avg. new words 32.78±11.49 68.33±13.46 -6.027 0.001** 
Animal naming Total new words 36.11±7.82 64.44±17.58 -4.418 0.001** 
Verbal N back- Hits 37.78±24.51 55.00±16.58 -1.746 0.100 
Verbal N back - Errors 39.67±17.81 54.78±27.73 -1.375 0.188 
Stroop effect 38.00±9.07 75.22±5.45 -10.554 0.001** 
AVLT - Memory score 21.56±8.55 65.56±16.09 -7.244 0.001** 
AVLT - Learning score 17.78±5.07 57.22±16.97 -6.679 0.001** 
AVLT - LTPR 14.33±8.96 53.33±18.71 -5.641 0.001** 
AVLT - Misses 24.89±6.95 32.56±25.73 -0.863 0.401 
AVLT - False alarms 73.22±40.52 87.44±24.94 -0.897 0.383 
CFT 20.33±14.94 58.33±16.22 -5.172 0.001** 
**P<0.01; *P<0.05 
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From the above table, it is inferred that there is a statistically significant difference 
between male schizophrenia patients group and male control group in the scores of 
DST total time, DVT total time, COWA average new words, animal naming total new 
words, stroop effect, AVLT-memory score, AVLT-learning score, AVLT-LTPR and 
CFT scores and this difference is also statistically significant (p<0.05).  In addition, 
the mean scores of the tests reveal that male control group people have high scores in 
the majority of the verbal and non-verbal tasks (except Verbal N Back Hits)  i.e. male 
schizophrenia patients group have poorer cognitive performance when compared with 
male control group.  The mean scores and standard deviations of each test is given in 
the table. 
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TABLE  3.3: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN FEMALE SCHIZOPHRENIA GROUP AND FEMALE 
CONTROL GROUP 
Neuropsychological tests 
Female 
Schizophrenia 
group  
Female 
Control 
t-Value P-value 
Mean±Sd 
DST total time 31.73±15.14 65.18±7.44 -6.577 0.001** 
DVT total time 24.09±7.70 61.64±9.44 -10.224 0.001** 
DVT errors 27.27±16.25 21.27±9.61 1.054 0.305 
COWA Avg. new words 35.36±25.85 60.45±13.86 -2.836 0.010** 
Animal naming Total new words 27.64±21.36 59.55±12.74 -4.255 0.001** 
Verbal N back- Hits 35.45±18.23 54.55±12.14 -2.891 0.009** 
Verbal N back - Errors 49.45±29.68 63.09±27.66 -1.115 0.278 
Stroop effect 50.82±30.48 72.91±8.28 -2.320 0.040* 
AVLT - Memory score 16.73±8.88 59.09±18.00 -7.000 0.001** 
AVLT - Learning score 12.55±8.37 56.82±16.17 -8.066 0.001** 
AVLT - LTPR 14.64±13.90 56.82±14.19 -7.043 0.001** 
AVLT - Misses 16.09±10.92 36.18±24.41 -2.492 0.022* 
AVLT - False alarms 87.18±28.77 90.00±22.47 -0.256 0.801 
CFT 22.09±6.86 59.18±14.19 -6.542 0.001** 
**P<0.01, *P<0.05 
Similar to the results from comparison of schizophrenia group and control group, on 
comparison of female schizophrenia patients group and female control group, the 
female schizophrenia group scored lower on DST total time, DVT total time, COWA 
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average new words, animal naming total new words, verbal N back-hits, stroop effect, 
AVLT-memory score, AVLT-learning score, AVLT-LTPR and CFT scores. This 
difference in scores was found to be statistically significant (p<0.05). The mean 
scores and standard deviations of each test is given in the table. reveal that female 
schizophrenia patients group have low level of cognitive compared with female 
control group.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 59 
TABLE  3.4: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN SCHOOL-LEVEL EDUCATED SCHIZOPHRENIA GROUP 
AND CONTROL GROUP 
Neuropsychological tests 
School-level 
educated 
Schizophrenia 
group 
School-
level 
educated 
Control 
t-Value P-value 
Mean±Sd 
DST total time 26.08±10.99 62.88±6.11 -9.012 0.001** 
DVT total time 25.67±6.00 58.33±10.56 -8.326 0.001** 
DVT errors 24.58±13.28 26.33±8.47 -0.345 0.734 
COWA Avg. new words 30.33±18.40 63.89±13.64 -4.594 0.001** 
Animal naming Total new words 23.25±12.07 54.44±13.33 -5.605 0.001** 
Verbal N back- Hits 36.67±25.88 47.78±13.94 -1.163 0.259 
Verbal N back - Errors 48.08±28.82 68.67±27.49 -1.651 0.115 
Stroop effect 43.50±26.09 71.89±7.78 -3.563 0.005** 
AVLT - Memory score 16.50±9.84 61.11±19.49 -6.292 0.001** 
AVLT - Learning score 12.75±8.56 58.33±16.20 -7.675 0.001** 
AVLT - LTPR 15.58±13.17 57.22±15.63 -6.621 0.001** 
AVLT - Misses 18.67±11.91 30.67±13.28 -2.176 0.042* 
AVLT - False alarms 75.33±36.89 88.11±23.75 -0.963 0.348 
CFT 19.50±8.54 55.56±15.09 -6.956 0.001** 
**P<0.01; *P<0.05 
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From the above table, it is inferred that there is a statistically significant difference 
(p<0.05) between the scores of school-level educated schizophrenia patients group 
and school- level educated control group on the following scores: of DST total time, 
DVT total time, COWA average new words, animal naming total new words, stroop 
effect, AVLT-memory score, AVLT-learning score, AVLT-LTPR, AVLT-Misses and 
CFT scores.  It is found that the school-level educated schizophrenia group showed a 
poorer performance than the school-level educated control group. There was no 
statistically significant difference in the performance on Verbal N back test Hits. The 
mean scores and standard deviations of each test is given in the table. 
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TABLE  3.5: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN COLLEGE LEVEL EDUCATED SCHIZOPHRENIA GROUP 
AND CONTROL GROUP 
Neuropsychological tests 
College-level 
educated 
Schizophrenia 
group 
College-
level 
educated 
Control 
t-Value P-value 
Mean±Sd 
DST total time 42.50±21.63 70.27±7.29 -3.491 0.008** 
DVT total time 22.00±15.27 57.27±9.11 -6.308 0.001** 
DVT errors 34.25±24.28 20.09±10.43 1.549 0.156 
COWA Avg. new words 40.00±22.68 64.09±14.80 -2.809 0.012** 
Animal naming Total new words 43.75±15.98 67.72±13.85 -3.495 0.003** 
Verbal N back- Hits 36.25±10.61 60.45±11.50 -4.675 0.001** 
Verbal N back - Errors 40.50±18.55 51.73±25.84 -1.045 0.311 
Stroop effect 47.37±21.39 75.63±6.28 -4.182 0.001** 
AVLT - Memory score 22.50±5.98 62.73±15.71 -7.756 0.001** 
AVLT - Learning score 18.12±3.72 55.91±16.71 -7.258 0.001** 
AVLT - LTPR 12.87±9.49 53.63±16.89 -6.126 0.001** 
AVLT - Misses 22.12±7.02 37.73±31.08 -1.609 0.135 
AVLT - False alarms 89.25±30.41 89.45±23.53 -0.017 0.987 
CFT 24.00±14.00 55.45±15.56 -4.531 0.001** 
**P<0.01, *P<0.05 
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Comparison of college-level educated schizophrenia patients and college-level 
educated control group revealed that college-level educated schizophrenia group had a 
statistically significant (p<0.05) poorer scores on DST total time, DVT total time, 
COWA average new words, animal naming total new words, verbal N back-hits, 
stroop effect, AVLT-memory score, AVLT-learning score, AVLT-LTPR and CFT 
scores. The mean scores and standard deviations of each test is given in the table. 
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SECTION IV: COMPARING SCHIZOPHRENIA PATIENTS WITH 
DURATION OF ILLNESS LESS THAN 2 YEARS AND THE PATIENTS 
WITH DURATION OF ILLNESS MORE THAN 2 YEARS 
TABLE 4.1: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN SCHIZOPHRENIA PATIENTS WITH DURATION OF 
ILLNESS BELOW 2 YEARS AND THE PATIENTS WITH DURATION OF 
ILLNESS ABOVE 2 YEARS 
Neuropsychological tests 
Duration of 
illness <2 
years 
Duration of 
illness > 2 
years 
t-Value P-value 
Mean±Sd 
DST total time 46.63±12.15 23.33±14.34 3.772 0.001** 
DVT total time 26.63±10.62 22.58±10.55 0.837 0.414 
DVT errors 22.63±17.24 32.33±19.03 -1.159 0.262 
COWA Avg. new words 31.88±9.23 35.75±25.41 -0.410 0.686 
Animal naming Total new words 35.63±9.79 28.67±20.24 0.899 0.381 
Verbal N back- Hits 33.13±14.38 38.75±25.41 -0.584 0.566 
Verbal N back - Errors 48.88±23.41 42.50±26.61 0.550 0.589 
Stroop effect 39.63±7.52 48.67±30.11 -0.825 0.420 
AVLT - Memory score 26.88±3.72 13.58±7.02 4.884 0.001** 
AVLT - Learning score 21.88±4.58 10.25±4.73 5.450 0.001** 
AVLT - LTPR 20.00±7.07 10.83±12.86 1.828 0.084 
AVLT - Misses 21.50±3.07 19.08±13.03 0.617 0.548 
AVLT - False alarms 100.00±00 68.17±39.90 2.764 0.018* 
CFT 28.13±10.33 16.75±9.07 2.602 0.018* 
IDEAS score 6.25±0.89 8.83±2.72 -3.051 0.009** 
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**P<0.01; *P<0.05 
From the above table, it is concluded that there is a statistically significant difference 
(p<0.05) between the scores of Neuropsychological testsamong schizophrenia patients 
with duration of illness less than 2 years and the patients with duration of illness more 
than 2 years, wherein those with >2years duration of illness scored poorer. This 
difference was seen in the scores of the following: moderately significant - AVLT-
false alarms and CFT; highly significant - DST total time, AVLT memory score, 
AVLT learning score and IDEAS score (P<0.01).  However, there is no statistical 
difference in the scores of DVT total time, DVT errors, COWA average new words, 
Animal naming total new words, verbal N back hits & errors, stroop effect, AVLT-
LTPR and AVLT Misses. 
FIGURE 3: MEAN SCORES CHART FOR NEUROPSYCHOLOGICAL 
TESTS’ SCORES IN SCHIZOPHRENIA PATIENTS WITH DURATION OF 
ILLNESS LESS THAN 2 YEARS AND SCHIZOPHRENIA PATIENTS WITH 
DURATION OF ILLNESS MORE THAN 2 YEARS 
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SECTION V: COMPARING THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS AMONG MALE AND FEMALE SCHIZOPHRENIA PATIENTS  
TABLE 5.1: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS BETWEEN SCHIZOPHRENIA MALE AND FEMALE PATIENTS 
Neuropsychological tests 
Male Female 
t-Value P-value 
Mean±Sd 
DST total time 33.78±21.17 31.73±15.14 0.252 0.804 
DVT total time 24.33±13.69 24.09±7.7 0.050 0.961 
DVT errors 29.89±21.91 27.27±16.25 0.307 0.763 
COWA Avg. new words 32.78±11.49 35.36±25.85 -0.277 0.785 
Animal naming Total new words 36.11±7.81 27.64±21.36 1.220 0.244 
Verbal N back- Hits 37.78±24.51 35.45±18.23 0.243 0.811 
Verbal N back - Errors 39.67±17.81 49.45±29.68 -0.867 0.397 
Stroop effect 38.00±9.07 50.82±30.48 1.325 0.210 
AVLT - Memory score 21.56±8.55 16.73±8.88 1.230 0.234 
AVLT - Learning score 17.78±5.07 12.55±8.37 1.641 0.118 
AVLT - LTPR 14.33±8.96 14.64±13.90 -0.056 0.956 
AVLT - Misses 24.89±6.95 16.09±10.92 2.089 0.051 
AVLT - False alarms 73.22±40.52 87.18±28.77 -0.900 0.380 
CFT 20.33±14.94 22.09±6.86 -0.326 0.751 
IDEAS score 6.89±1.83 8.55±2.81 -0.085 0.145 
  
Independent sample t test clearly reveals that there is no statistically 
significant difference between male and female schizophrenia patients on the scores 
of all Neuropsychological tests and IDEAS score. (p>0.05) 
 66 
SECTION VI: COMPARING THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS AMONG SCHOOL-LEVEL EDUCATED SCHIZOPHRENIA 
PATIENTS AND COLLEGE-LEVEL EDUCATED SCHIZOPHRENIA 
PATIENTS  
TABLE 6.1: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS AMONG SCHOOL LEVEL EDUCATED SCHIZOPHRENIA PATIENTS 
AND COLLEGE LEVEL EDUCATED SCHIZOPHRENIA PATIENTS 
Neuropsychological tests 
School level 
College 
level t-Value P-value 
Mean±Sd 
DST total time 26.08±11.00 42.50±21.63 -1.983 0.077 
DVT total time 25.67±6.00 22.00±15.27 0.647 0.535 
DVT errors 24.58±13.28 34.25±24.28 -1.028 0.328 
COWA Avg. new words 30.33±18.40 40.00±22.68 -1.050 0.308 
Animal naming Total new words 23.25±12.08 43.75±15.98 3.272 0.004** 
Verbal N back- Hits 36.67±25.88 36.25±10.61 0.043 0.966 
Verbal N back - Errors 48.08±28.82 40.50±18.55 0.656 0.520 
Stroop effect 43.50±26.09 47.38±21.39 -0.348 0.732 
AVLT - Memory score 16.50±9.84 22.50±5.97 -1.538 0.141 
AVLT - Learning score 12.75±8.56 18.13±3.72 -1.920 0.073 
AVLT - LTPR 15.58±13.17 12.88±9.49 0.500 0.623 
AVLT - Misses 18.67±11.91 22.13±7.02 -0.736 0.471 
AVLT - False alarms 75.33±36.89 89.25±30.41 -0.883 0.389 
CFT 19.50±8.54 24.00±14.00 -0.897 0.382 
IDEAS score 8.67±2.84 6.50±1.07 2.401 0.030* 
**P<0.01; P<0.05 
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Independent sample t test is used to analyze and compare the scores between school-
level educated schizophrenia patients and college-level educated schizophrenia 
patients.  There is a statistically significant difference in the performance between the 
two groups on Animal naming test – Total new words and IDEAS score(p<0.05). In 
Animal naming test, college-educated schizophrenia patients has higher scores. In 
IDEAS, school-educated schizophrenia patients have scored higher. However, there is 
no significant difference in the scores of the rest of the neuropsychological tests 
between these two groups. 
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SECTION VII: COMPARING THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS AMONG DIFFERENT AGE GROUP IN SCHIZOPHRENIA 
PATIENTS   
 
TABLE 7.1: DIFFERENCE IN THE SCORES OF NEUROPSYCHOLOGICAL 
TESTS AMONG DIFFERENT AGE GROUP  IN SCHIZOPHRENIA PATIENTS 
Neuropsychological tests 
18-30 years 31-50 years 51-65 years 
P-value 
Mean±Sd 
DST total time 41.38±18.75 26.40±15.92 29.00±11.31 0.197 
DVT total time 24.13±13.76 24.10±9.12 25.00±4.24 0.994 
DVT errors 24.88±17.12 33.70±20.31 16.50±9.19 0.401 
COWA Avg. new words 34.38±8.21 39.50±24.77 7.00±4.24 0.113 
Animal naming Total new words 35.63±9.79 30.40±21.92 20.00±0.0 0.509 
Verbal N back- Hits 31.88±14.12 41.50±25.93 30.00±14.14 0.580 
Verbal N back - Errors 41.38±21.94 46.30±30.10 53.50±4.95 0.824 
Stroop effect 38.38±6.50 49.70±28.29 48.50±51.61 0.616 
AVLT - Memory score 26.25±5.17 13.30±6.98 17.50±10.61 0.003** 
AVLT - Learning score 21.88±4.58 10.30±4.67 10.00±7.07 0.001** 
AVLT - LTPR 19.88±7.38 7.70±3.80 27.00±32.53 0.015* 
AVLT - Misses 21.50±3.07 18.10±13.01 24.00±16.97 0.683 
AVLT - False alarms 89.25±30.41 78.30±35.48 60.50±55.86 0.564 
CFT 25.50±13.44 17.70±8.95 22.50±3.53 0.336 
IDEAS score 6.38±1.06 8.40±2.41 10.50±4.95 0.055* 
**P<0.01; *P<0.05 
Analysis of variance (ANOVA) test has been used to determine the difference in the 
scores of the neuropsychological tasks among different age groups of schizophrenia 
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patients.  The statistically significant difference was seen among the different age 
groups in AVLT memory score, AVLT learning score and AVLT LTPR. The 
schizophrenia patients in the age group 18-30 years have the highest scores in AVLT 
memory score and AVLT learning score. The mean and standard deviations of the 
scores are given in the above table.It was also seen that,  schizophrenia patients in 18-
30 years group have milder disability, patients in 31-50 years have moderate level of 
disability and patients in 51-65 years group have severe disability.  
SECTION VIII: RELATIONSHIP BETWEEN DISABILITY SCORES AND 
NEUROCOGNITIVE TEST SCORES AMONG SCHIZOPHRENIA 
PATIENTS 
 
FIGURE 4: PIE CHART FOR PERCENTAGE OF DISABILITY IN 
SCHIZOPHRENIA PATIENTS 
 
 
 
30.0% 
65.0% 
5.0% 
Level of Disability
Mild
Moderate
Severe
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It is noted from the above figure that 65% of schizophrenia patients have a disability 
score percentage > 40%, thus making this 65% eligible for the welfare measures given 
by the Government of India.  
TABLE 8.1: CORRELATION BETWEEN SCORES IN EACH DOMAIN OF 
IDEAS AND NEUROCOGNITIVE TESTS‟ SCORES IN THE SCHIZOPHRENIA 
PATIENTS 
Neuropsychological 
tests 
IDEAS self-
care 
IDEAS 
interpersonal 
activities 
IDEAS 
communication 
& interaction 
IDEAS work 
r-value (P-value) 
DST total time -.021 (0.930) -.078 (0.743) -.189 (0.425) -.484 (0.031*) 
DVT total time -.128 (0.590) .259 (0.270) -.042 (0.861) -.356 (0.123) 
DVT errors -.035 (0.883) -.302 (0.196) -.584 (0.007**) .307 (0.188) 
COWA Avg. new 
words 
-.021 (0.931) -.318 (0.172) -.134 (0.573) -.220 (0.352) 
Animal naming 
Total new words 
-.204 (0.389) -.238 (0.312) -.278 (0.235) -.073 (0.760) 
Verbal N back- Hits -.217 (0.359) -.010 (0.967) .305 (0.191) -.226 (0.339) 
Verbal N back - 
Errors 
.162 (0.494) -.287 (0.220) .058 (0.809) -.435 (0.055) 
Stroop effect -.138 (0.561) -.373 (0.105) -.338 (0.144) -.262 (0.264) 
AVLT - Memory 
score 
-.339 (0.144) -.200 (0.397) -.387 (0.091) -.222 (0.346) 
AVLT - Learning 
score 
-.384 (0.094) -.172 (0.467) -.368 (0.111) -.002 (0.994) 
AVLT - LTPR -.399 (0.082) -.188 (0.428) -.179 (0.451) -.270 (0.250) 
AVLT - Misses -.126 (0.596) .059 (0.806) .342 (0.140) .272 (0.246) 
AVLT - False 
alarms 
.021 (0.931) -.049 (0.837) -.333 (0.151) -.365 (0.114) 
CFT -.054 (0.822) -.041 (0.862) -.207 (0.380) -.213 (0.367) 
**P<0.01, *P<0.05 
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Pearson correlation coefficient values indicate that IDEAS score in each domain such 
as self-care and interpersonal activities does not have a linear relationship with any of 
the neuropsychological test scores. However, the disability score in the domain 
„Communication and Understanding‟ is seen to have a linear negative relationship 
with DVT errors and the disability score in the domain „Work‟ has a linear negative 
relationship with DST total time.   
 
TABLE 8.2: CORRELATION BETWEEN IDEAS GLOBAL SCORE AND 
NEUROPSYCHOLOGICAL TESTS‟ SCORES IN THE SCHIZOPHRENIA 
PATIENTS 
Neuropsychological tests 
IDEAS Global score 
r-value P-value 
DST total time -.537 .015* 
DVT total time -.191 .421 
DVT errors -.092 .699 
COWA Avg. new words -.231 .327 
Animal naming Total new words -.292 .212 
Verbal N back- Hits .037 .879 
Verbal N back - Errors -.201 .395 
Stroop effect -.251 .287 
AVLT - Memory score -.635 .003** 
AVLT - Learning score -.591 .006** 
AVLT - LTPR -.406 .076 
AVLT - Misses .203 .391 
AVLT - False alarms -.489 .028* 
CFT -.453 .045* 
**P<0.01; *P<0.05 
The statistical significance (P<0.05) clearly reveals there is a linear relationship 
between the disability score (IDEAS global score) and the scores of 
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neuropsychological tests such as DST total time, AVLT-memory score, AVLT-
learning score, AVLT-False alarms and CFT. Pearson correlation coefficient values of 
these variables are negative that implies such relationship is negative.  i.e., The 
disability score decreases when the neuropsychological tests‟ (mentioned above) 
score increases. 
Figure 5: Relationship between DST total time and IDEAS Global score 
 
Figure 6: Relationship between AVLT-memory score and IDEAS Global score 
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Figure 7: Relationship between AVLT-learning score and IDEAS Global score 
 
 
Figure 8: Relationship between AVLT-False alarms and IDEAS Global score 
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Figure 9: Relationship between CFT and IDEAS Global score 
 
 
 
The trend line in above figures (Figures 5-9) depicts that the IDEAS Global score 
decreases when the scores of DST total time, AVLT memory score, AVLT learning 
score, AVLT false alarms and CFT increases. Thus, a negative correlation is observed 
between the IDEAS global score and the neuropsychological test scores that are 
mentioned above. 
 
 
  
 
 
 
 75 
DISCUSSION 
 
Our study aimed at finding the domains of neurocognitive deficits in clinically stable 
schizophrenia compared to an age and gender matched healthy control group. 
However, educational status is not matched in our control group. As a previous study 
(14)
 has mentioned, without having a conclusive evidence about the onset of cognitive 
deficits in schizophrenia that could have affected the level of education, matching for 
education may give spuriously low estimates of the intellectual ability of the 
schizophrenia patients. Using validates Indian tools, we analyzed both the 
neurocognitive deficits and disability in Indian population. The findings from the 
study are as follows. 
 
 
NEUROCOGNITIVE DEFICITS IN SCHIZOPHRENIA 
 
Our study found that, on comparing with control group, patients with Schizophrenia 
have deficits in all the assessed domains, such as attention, processing speed, 
executive functions (fluency, working memory and response inhibition), verbal 
learning and memory, visual-spatial construction and visual memory. This is similar 
to the findings from the previous studies done in the same area.
(14,17)
 A similar study 
done in Indian population assessing attention, executive function, verbal and visual 
learning & memory using neuropsychological tests developed in other cultures, also 
showed a similar profile of cognitive impairments. 
(39)
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When sub-group analyses were done in our study based on gender and education, the 
results did not differ much, showing statistically significant deficits in all 
neurocognitive domains among the schizophrenia patients. One interesting finding in 
our study is that, when sub-group analyses was done among males (schizophrenia Vs 
controls), although the mean scores were higher in the male control group, it failed to 
show statistically significant difference between the two groups in working memory 
task (Verbal N back test). This is in contrary to the previous studies which showed 
that, irrespective of gender, all neurocognitive domains were impaired in 
Schizophrenia. 
(30,53)
A previous study done by Malaspina et al., showed that males are 
seen to have slightly better working memory than females. 
(59)
 One explanation is that, 
because males have a better working memory function innately, we did not see 
significant deficits when compared with healthy male controls.  
 
 
Another finding from sub-group analysis is that, among participants with school-level 
education, the control group scored higher than schizophrenia patients on working 
memory testing, but this was not statistically significant. Although this is contrary to 
the majority of the studies showing poor premorbid level of education is a predictor of 
poor performance on neurocognitive tests
(7,26,30)
, it could be explained by the concept 
that neurocognitive deficits in schizophrenia fall on a continuum (Heinrichs and 
Zakzanis, 1998). That is, there may be an overlap between schizophrenia patients with 
mild cognitive deficits (in our study, mild deficit in working memory) and healthy 
controls.  
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Thus, we can safely conclude that those with schizophrenia has impaired 
neurocognitive functioning in all the domains that were assessed.  
 
 
NEUROCOGNITION & DURATION OF ILLNESS 
 
In the clinically stable Schizophrenia group, it was found that patients with duration 
of illness more than 2 years have more deficits in speed of processing, verbal learning 
and memory, visual memory and visuo-spatial construction. Previously, various 
prospective and cross-sectional studies
(6.8.13.17)
 have shown that the cognitive deficits 
in schizophrenia appear to stabilize over time i.e., no worsening of cognitive deficits 
with increasing duration of illness. Similar results were given by a large-scale meta-
analysis done in 2013 which found no significant relationship between neurocognitive 
deficits and duration of illness.
(2)
 Our study found that, in some of the neurocognitive 
domains, there were more deficits in patients with longer duration of illness, whereas 
some of the domains appear to have improved with longer duration of illness. 
 
 
Many studies have showed that verbal learning and memory is the most consistent 
deficit which is seen to decline with longer duration of illness. A prospective study by 
Haring et al., observed that verbal learning and memory and visuo-spatial recognition 
declined with time.
(7)
 This is similar to the finding from our study, which showed that 
patients with duration of illness more than 2 years, have significantly more deficits in 
verbal learning & memory and visuo-spatial construction and visual memory.  
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Our study also reported more deficits in processing speed among patients with longer 
duration of illness. Gonzalez-Ortega et al., in a 5 year follow-up study found that, no 
improvement in processing speed was observed over time, although most of the other 
neurocognitive domains appeared to have improved. Majority of the studies have 
found that the neurocognitive deficits become stable with time, but some studies have 
even showed that processing speed have improved over time, 
(4,7)
 which is contrary to 
our study results. We could not find an explanation for this contradicting result in our 
study. 
 
 
Haring et al., in his prospective study, found that executive function and working 
memory improves with time.Similar results have been seen in other studies, that 
executive function and working memory improves as the duration of illness increases. 
(6,47)
 In our study, among the schizophrenia patients, those with more than 2 years of 
illness i.e., longer duration of illness showed higher scores on working memory and 
execution function (response inhibition and fluency) tests than those with duration of 
illness less than 2 years. But, this difference was not statistically significant.  
 
 
Hence, we conclude that, the stability of neurocognitive deficits in schizophrenia still 
needs to be explored further. 
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NEUROCOGNITION AND SOCIODEMOGRAPHIC FACTORS  
 
Owing to the differences in the neurobiology of the male and female brain, gender 
differences are theoretically expected in age of onset, clinical symptomatology, 
treatment response and prognosis in schizophrenia. A large cohort study done by 
Goldberg and James et al., did not find any significant difference in the performances 
of males and females on all neurocognitive tests. 
(56)
 In our study, among the patients 
with Schizophrenia, when sub-group analysis was done based on age, we found that 
there is no statistically difference between the scores of male and female 
schizophrenics on all neurocognitive tests. Both the genders have a similar profile of 
neurocognitive impairment. But, this is in contrary to the findings from few other 
studies which showed that females had a better performance than males in learning & 
memory, processing speed and executive function, thereby predicting a poorer 
outcome in males.
(2,7,30)
 Thus, gender differences in neurocognition among 
schizophrenia patients still remains controversial and needs to be explored in further 
research. 
(57) 
 
Previous studies with a similar study design have found that, the neurocognitive 
functioning seem to decline with age i.e., as age increased, the deficits in domains 
such as  
 
processing speed and memory become more.
(30)
 An Indian study showed similar 
results that memory and attention decline with increasing age. 
(53) 
Our study results 
revealed that although there is a decline in verbal learning in memory scores, those in 
the age group of 51-65 years showed a higher score than those in the age group of 31-
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50 years, which was also found to be statistically significant. The same trend was 
observed in various other domains such as processing speed, working memory, visual 
memory and visuo-spatial reconstruction, those differences were not statistically 
significant. This finding from our study can be explained by the number of patients in 
each age group, with the least (only 2) in the 51-65 age group (against 9 participants 
in the other 2 age groups). Thus, future studies should take this into account and have 
a comparable number of participants in each age group.  
 
Some of the studies done previously, have found a significant correlation between 
education and cognitive functioning in Schizophrenia patients. They have found that a 
better educational status is associated with a better cognitive performances.
(7,26,53)
 Our 
study also showed similar results that, in majority of the cognitive domains assessed, 
college-level educated participants scored higher than those with school-level 
education. Though, statistically significant difference was noted only for fluency task, 
which is an executive function. That is, college-level educated schizophrenia patients 
scored significantly higher on executive function domain. But, this has not always 
been the case. Studies have also showed that has no significant correlation with 
neurocognitive functioning, and this is especially true in the normal controls.
(26)
 
Hence, even though studies have found an association, we have no conclusive 
evidence about the directionality of this relationship. It could be, either, that 
Schizophrenics with a premorbid better cognition are able to reach a higher 
educational status and thus have a better cognitive performance even after the onset of 
schizophrenia or that people with premorbid lower level of education are susceptible 
for poorer cognitive functioning following the onset of schizophrenia. As of now, we 
 81 
don‟t have evidence to conclusively say that education is a protective factor for 
cognitive deficits in Schizophrenia. 
 
DISABILITY & NEUROCOGNITION IN SCHIZOPHRENIA 
 
Functional outcome is an important area of interest in Schizophrenia for many 
researchers. The studies that have been done so far have established a clear correlation 
between cognitive deficits and poor functional outcome in domains such as self-care, 
community participation, interpersonal relations independent living skills and work 
skills.
(4,1518)
 Studies have also found an association between negative symptoms and 
cognitive deficits, especially verbal learning and memory impairment.
(4,13,53)
 Based on 
this, a model has been hypothesized that, negative symptoms mediates the negative 
correlation between neurocognition and functional competence in Schizophrenia. 
(15)
 
 
 
We assessed the functional outcome of schizophrenia patients in terms of disability 
using IDEAS scale, which is developed specially for the Indian population. Our study 
found that, there is a negative correlation between disability among schizophrenia 
patients (based on the global score on IDEAS scale) and neurocognitive functioning, 
which is similar to the findings from the earlier studies. Among the neurocognitive 
domains, processing speed, verbal learning and memory, visual memory and visuo-
spatial construction are found to have statistically significant negative correlation with 
disability. Previous studies
(4,32,42)
 have also showed that, among the domains of 
neurocognition, processing speed, attention, verbal learning and memory and visuo-
spatial constructional ability were necessary for real-world functional competence. 
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When correlation with each domain of the disability scale – self-care, interpersonal 
activities, communication and understanding and work, was analyzed, we found that 
processing speed and disability in work was significantly correlated in a negative 
manner i.e., more the deficits in processing speed, more is the disability in work 
domain. This finding is similar to the results from the previous studies.
(18,32)
 It was 
noted that, when domains of functioning are individually analyzed for correlation with 
deficits in each neurocognitive domain, only processing speed was found to be 
significantly correlated, but not verbal learning and memory, visual memory and 
visuo-spatial construction which were significantly correlated with the global 
disability scores, as discussed earlier. One explanation for this loss of significance on 
breaking down the global disability score into its component scores, could be that, the 
global score includes an additional score for duration of illness and upon removal of 
which, the statistical significance for verbal learning and memory & visual memory is 
lost. Thereby, it again adds evidence to the earlier described result of verbal learning 
and memory, visual memory and visuo-spatial construction being significantly 
associated with duration of illness in schizophrenia.  
 
 
Thus, we found that few domains of neurocognition have a significant relationship 
with the functional outcome in schizophrenia. Improving these specific domains of 
neurocognitive deficits may improve the functional outcome and thereby, quality of 
life of schizophrenia patients 
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DISABILITY AND OTHER FACTORS 
 
When factors such as age, gender and education are analyzed for its association with 
disability, we found that, disability score has a significant association with increasing 
age. i.e., the disability is observed to be more in older age group, thereby predicting a 
poorer functional outcome with increasing age. Some previous studies
(30,53)
 have 
suggested that, there is worsening of some neurocognitive deficits with ageing, and 
the relationship between disability and cognitive functioning is well-established from 
our study and various other studies. This could be a reason for worsening of disability 
with age found in our study. 
 
 
When disability among males and females were compared, our study found that males 
have higher disability than females, although it was not statistically significant.  This 
is similar to the results from the previous studies which reported that males have 
poorer functional outcomes compared to females.
(2,7,30)
 Few other studies have 
reported that, owing to the better psychosocial functioning among males, males have a 
better functional outcome than females with schizophrenia. Thus, gender differences 
in functional outcome still remains controversial. 
 
 
Based on level of education, we found that, school-level educated schizophrenia 
patients have significantly higher disability than college-level educated 
schizophrenics. Even though, previous studies have showed that, better premorbid 
level of education is a predictor of better outcome in  
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schizophrenia, contradicting results suggesting no relationship between education and 
functional outcome have also been observed. Hence, the relationship between 
education and functional outcome still needs to be explored.  
 
Similar to the controversial association of neurocognitive deficits and 
sociodemographic variables, the association between functional outcome and 
sociodemographic variables are also equally controversial. Further research is needed 
to come to a conclusion regarding these associations. 
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STRENGTHS 
 
1. We studied the cognitive functioning of patients with clinically stable 
schizophrenia and compared it with that of a healthy control group, thereby 
enabling us to analyze the differences in performance between those with 
schizophrenia and the normal population.  
 
 
2. Our study included a control group that is age and gender matched with the 
schizophrenia patients, thus enabling a better comparison between the 
neurocognition in healthy people and those with schizophrenia. 
 
 
3. Our study was done in patients with clinically stable schizophrenia where we 
assessed the remission by using a standardized scale i.e., PANSS and a 
standardized criterion for remission (given by Nancy Andreasen). 
 
 
4. Among the participants with schizophrenia, we divided them into 2 groups as 
those with duration of illness less than 2 years and those with duration of illness 
more than 2 years. Thus, we were able to analyze the differences in the domains 
of deficits in relation to the duration of illness. 
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5. We used the NIMHANS Neuropsychological Battery, a validated assessment tool 
developed in the Indian context with normative data for the Indian population. 
 
 
6. We used a Disability assessment scale which is specifically used for the Indian 
population, thereby eliminating the cultural variations which may potentially 
influence the results.  
 
 
7. We correlated the functional outcome and neurocognitive deficits by analyzing the 
relationship between disability in each domain of functioning with the domains of 
cognitive impairment.  
 
 
8.  We explored the relationship between functional outcome and duration of 
schizophrenia by comparing the disability in those with duration of illness less 
than 2 years and those with duration of illness more than 2 years.  
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LIMITATIONS 
 
In our study, we had some limitations that are worthwhile to be mentioned.  
 
1. The sample size for our study was small which could have influenced the results 
and limits the generalizability of our findings. Similar studies with a larger sample 
size can be more beneficial to bring a better understanding about the impairments 
of the schizophrenia patients. 
 
2. We used a convenient sampling method which could have led to selection bias, 
thereby affecting the results of the study. A consecutive sampling method or 
stratified sampling method may be used in future studies. 
 
3. Blinding of the assessor was not done that could have led to potential bias in the 
scoring of the neuropsychological assessment. 
 
4. Among the neurocognitive domains that are proposed to be important in 
schizophrenia, our study did not analyze the domains of reasoning & problem 
solving and social cognition. 
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CONCLUSION 
 
Our study in the Indian population found that there is significant amount of 
impairments in neurocognition among schizophrenia patients and some of these 
impairments appear to worsen over time. We also found that the functional outcome 
of schizophrenia largely depends on few of the domains of cognitive deficits seen in 
these patients. Cognitive retraining for these specific cognitive deficits, given early in 
the course of illness may improve the functional outcome in schizophrenia patients 
and thereby patients with schizophrenia may no longer be considered as “life-long 
disabled”. Pharmacological and non-pharmacological treatment strategies for 
improving neurocognitive impairments is the need of the hour. 
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Study Volunteer ID:                                                   
Study Volunteer Name:  
Page 1 of 2 
 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
 
I , Dr. Sheerin Fathima carrying out a study on the topic: “Neurocognition and disability in patients with 
Schizophrenia compared with healthy controls” as part of my / our research project being carried out under the 
aegis of the Department of: Psychiatry  
 
(Applicable to students only): My research guide is: Dr I Anand 
 
 
 
 
 
The objectives of this study are:  
 
Primary Objective: The aim of the study is to assess the neurocognitive functions among patients with clinically 
stable Schizophrenia and compare with healthy controls. 
 
Secondary Objective:  To compare the neurocognitive functions in clinically stable Schizophrenia patients with 
illness duration of less than 2 years and more than 2 years. 
                                   To correlate the degree of disability with neurocognitive functions comparing 
schizophrenia patients and healthy controls. 
 
 
Sample size: ___50 schizophrenia patients and 50 healthy controls___.  
 
Study volunteers / participants are (specify population group & age group): >18 – 60 years 
Location: PSGIMSR, Coimbatore  
 
We request you to kindly cooperate with us in this study. We propose collect background information and other 
relevant details related to this study. We will be carrying out:  
 
Initial interview (specify approximate duration):___60___ minutes.  
 
Data collected will be stored for a period of _NA_ years. We will / will not use the data as part of another study. 
 
Health education sessions: Number of sessions: ______NA_______. Approximate duration of each session:  
 
_______NA_______ minutes.  
 
Clinical examination (Specify details and purpose): NA 
 
Blood sample collection: Specify quantity of blood being drawn: _____NA______ml.  
 
No. of times it will be collected: ________NA_______.  
 
Whether blood sample collection is part of routine procedure or for research (study) purpose:  NA 
 
1. Routine procedure 2. Research purpose  
Study Volunteer ID:                                                   
Study Volunteer Name:  
Page 2 of 2 
 
 
Specify purpose, discomfort likely to be felt and side effects, if any: _______________NA________________ 
 
Whether blood sample collected will be stored after study period: NA 
 
Whether blood sample collected will be sold:  NA 
 
Whether blood sample collected will be shared with persons from another institution:   NA 
 
Medication given, if any, duration, side effects, purpose, benefits: NA 
 
Whether medication given is part of routine procedure:NA 
 
Final interview (specify approximate duration):_____NA__ mts. If photograph is taken, purpose: NA 
 
Benefits from this study: NA 
 
Risks involved by participating in this study: NA 
 
How the results will be used:  
 
If you are uncomfortable in answering any of our questions during the course of the interview / biological sample 
collection, you have the right to withdraw from the interview / study at anytime. You have the freedom to 
withdraw from the study at any point of time. Kindly be assured that your refusal to participate or withdrawal at 
any stage, if you so decide, will not result in any form of compromise or discrimination in the services offered nor 
would it attract any penalty. You will continue to have access to the regular services offered to a patient. You will 
NOT be paid any remuneration for the time you spend with us for this interview / study. The information 
provided by you will be kept in strict confidence. Under no circumstances shall we reveal the identity of the 
respondent or their families to anyone. The information that we collect shall be used for approved research 
purposes only. You will be informed about any significant new findings - including adverse events, if any, – 
whether directly related to you or to other participants of this study, developed during the course of this research 
which may relate to your willingness to continue participation. 
 
Consent: The above information regarding the study, has been read by me/ read to me, and has been 
explained to me by the investigator/s. Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to indicate my consent and willingness to 
participate in this study (i.e., willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal Representative:  
 
 
Signature of the Interviewer with date:      Witness: 
 
Contact number of PI: +91 9486170816 
 
Contact number of Ethics Committee Office:  0422 4345818  
 
G+ rh Nfh kUj;Jtf; fy;Y}hp kw;Wk; Muha;r;rp epWtdk;, Nfhit 
kdpj newpKiwf; FO 
Xg;Gjy; gbtk; 
       Njjp: 
lhf;lH. m. \Phpd; ghj;jpkh Mfpa ehd;.  G+ rh Nfh kUj;Jtf; fy;Yhhpapd; / kUj;Jt 
kidapd; kdey kUj;Jtj; Jiwapd; fPo; “kdr;rpijT Nehahspfspd; euk;gpay; 
GyDzHT nray;ghL kw;Wk; nray;jpwd; – XH xg;gPL” vd;w jiyg;gpy; Ma;T 
Nkw;nfhs;s  cs;Nsd;. 
vd; Ma;T topfhl;b (khztHfSf;F kl;Lk;) : lhf;lH. Mde;j;. I 
 
Ma;T Nkw;nfhs;tjd; mbg;gil 
kdr;rpijT Nehahspfspd; euk;gpay; GyDzHT nray;ghl;by; FiwghLfs; ntFthff; 
fhzg;gLfpd;wd.  Mifahy; ,e;j Ma;tpd; %yk; mtw;wpd; jd;ik kw;Wk; 
NtWghLfis mwpe;J nfhs;stpUf;fpNwd;. 
Ma;tpd; Nehf;fk; :.. 
kdr;rpijT Nehahspfspd; euk;gpay; GyDzHT nray;ghL kw;Wk; nray;jpwd; gw;wp 
njhpe;J nfhs;Sjy;  mjd;%yk; Nehahspfspy; fhzg;gLk; FiwghLfis 
Nehaw;wtHfNshL xg;gpLjy;. 
Ma;tpy; gq;F ngWk; egHfspd; vz;zpf;if: 50 Nehahspfs; 
          50 Nehaw;wtHfs; 
Ma;tpy; gq;F ngWNthH kw;Wk; taJ : >18 - 60 
 
Ma;T Nkw;nfhs;Sk; ,lk; : 
G+ rh Nfh kUj;Jtkid. Nfhak;Gj;JhH 
 
,e;j Ma;tpy; vq;fSld; xj;Jiof;FkhW Nfl;Lf;nfhs;fpNwhk;.  ehq;fs; rpy 
jfty;fis ,e;j Ma;tpw;fhf Nrfhpf;f cs;Nshk;.  
 
 
 
Ma;T nra;ag;gLk; Kiw :  
  
Kjd;ik NeH fhdy; : 60 epkplq;fs; 
,e;j Ma;tpy; fpilf;Fk; jfty;fs;          tUlq;fs; ghJfhf;fg;gLk;  ,e;j 
jfty;fs; NtW Ma;tpw;Fg; gad;gLj;jg;gLk; / gad;gLj;jg;gl khl;lhJ.     nghUe;jhJ 
Rfhjhuf; fy;tp : nghUe;jhJ 
 
kUj;Jt ghpNrhjidfs;  : nghUe;jhJ 
 
,uj;j khjphp Nrfhpg;G   : nghUe;jhJ 
 
,uj;j khjphp vLg;gJ tof;fkhd rpfpr;irf;fhfth my;yJ ,e;j Ma;tpw;fhfth? 
 
 : nghUe;jhJ 
 
,jdhy; Vw;glf; $ba mnrsfhpaq;fs;   gf;f tpisTfs;   : nghUe;jhJ 
 
,uj;j khjphpfs; Ma;tpw;Fg; gpd; ghJfhj;J itf;fg;gLkh?     : nghUe;jhJ 
 
Nrfhpf;fg;gl;l ,uj;jk; NtW epWtdj;Jld; gfpHe;J nfhs;sg;gLkh? : nghUe;jhJ 
 
kUe;Jfs; VNjDk; nfhLf;fg;gltpUe;jhy; mit gw;wpa tptuk; (nfhLf;fg;gLk; fhuzk;, 
gf;f tisTfs;  gad;fs;) : nghUe;jhJ 
 
kUe;Jfs; nfhLf;fg;gLtJ tof;fkhd rpfpr;ir Kiwah? : nghUe;jhJ 
 
nfhLf;fg;gLk; kUe;JfSf;F khw;W cs;sjh? : nghUe;jhJ 
 
Ma;tpy; gq;F ngWtjhy; Vw;gLk; gyd;fs;  : nghUe;jhJ 
 
Ma;tpy; gq;Nfw;gjhy;  Vw;gLk; mnrsfhpaq;fs;   gf;f tpisTfs;  : nghUe;jhJ 
 
 
Ma;tpd; KbTfs; ve;j Kiwapy; gad;gLj;jg;gLk;? 
 
 
Ma;Tf;Fl;gLgthpd; xg;Gjy; : 
 
ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp njspthfTk;. 
Tpsf;fkhfTk; njhpag;gLj;jg;glLs;Nsd;.  ,e;j Muha;r;rpapy; gq;F nfhs;sTk;.  ,e;j 
Muha;r;rpapd; kUf;Jt hPjpahd Fwpg;Gfis tUk; fhyj;jpYk; cgNahfg;gLj;jpf; 
nfhs;sTk; KO kdJld; rk;kjpf;fpNwd;.    
 
Ma;Tf;Fl;gLgthpd;  ngaH. Kftup  :  
Njjp      : 
 
Ma;thshpd; ifnahg;gk;  : 
Njjp    : 
 
Ma;thshpd; njhiyNgrp vz;   : 9486170816 
 
newpKiw FO mYtyf njhiyNgrp vz; : 0422 – 2570170  cs;njhlHG vz;  : 5818 
 
P A N S S  R A T I N G  F O R M  
 
  absent minimal mild moderate moderate 
severe 
severe extreme
         
P1 Delusions 1 2 3 4 5 6 7 
P2 Conceptual disorganisation 1 2 3 4 5 6 7 
P3 Hallucinatory behaviour 1 2 3 4 5 6 7 
P4 Excitement 1 2 3 4 5 6 7 
P5 Grandiosity 1 2 3 4 5 6 7 
P6 Suspiciousness/persecution 1 2 3 4 5 6 7 
P7 Hostility 1 2 3 4 5 6 7 
         
N1 Blunted affect 1 2 3 4 5 6 7 
N2 Emotional withdrawal 1 2 3 4 5 6 7 
N3 Poor rapport 1 2 3 4 5 6 7 
N4 Passive/apathetic social withdrawal 
1 2 3 4 5 6 7 
N5 Difficulty in abstract thinking 1 2 3 4 5 6 7 
N6 Lack of spontaneity & flow of conversation 
1 2 3 4 5 6 7 
N7 Stereotyped thinking 1 2 3 4 5 6 7 
         
G1 Somatic concern 1 2 3 4 5 6 7 
G2 Anxiety 1 2 3 4 5 6 7 
G3 Guilt feelings 1 2 3 4 5 6 7 
G4 Tension 1 2 3 4 5 6 7 
G5 Mannerisms & posturing 1 2 3 4 5 6 7 
G6 Depression 1 2 3 4 5 6 7 
G7 Motor retardation 1 2 3 4 5 6 7 
G8 Uncooperativeness 1 2 3 4 5 6 7 
G9 Unusual thought content 1 2 3 4 5 6 7 
G10 Disorientation 1 2 3 4 5 6 7 
G11 Poor attention 1 2 3 4 5 6 7 
G12 Lack of judgement & insight 1 2 3 4 5 6 7 
G13 Disturbance of volition 1 2 3 4 5 6 7 
G14 Poor impulse control 1 2 3 4 5 6 7 
G15 Preoccupation 1 2 3 4 5 6 7 
G16 Active social avoidance 1 2 3 4 5 6 7 
 
M.I.N.I. 5.0.0 (July 1, 2006) 2
Patient Name: Patient Number:  
Date of Birth:  Time Interview Began:  
Interviewer’s Name: Time Interview Ended:  
Date of Interview:  Total Time:  
    
 
  MEETS 
 MODULES TIME FRAME CRITERIA DSM-IV ICD-10 
 
A MAJOR DEPRESSIVE EPISODE Current (2 weeks)   296.20-296.26  Single F32.x  S 
  Recurrent   296.30-296.36  Recurrent F33.x  S  
   
 MDE WITH MELANCHOLIC FEATURES Current (2 weeks)   296.20-296.26  Single F32.x  S 
 Optional    296.30-296.36  Recurrent F33.x  S 
 
B DYSTHYMIA Current (Past 2 years)   300.4  F34.1  S 
 
C SUICIDALITY Current (Past Month)       S 
  Risk:  Low   Medium   High 
 
D MANIC EPISODE Current   296.00-296.06  F30.x-F31.9 S 
  Past   
 HYPOMANIC EPISODE Current   296.80-296.89  F31.8-F31.9/F34.0 S 
  Past   
 
E PANIC DISORDER Current (Past Month)   300.01/300.21  F40.01-F41.0 S 
  Lifetime   
 
F AGORAPHOBIA Current   300.22  F40.00 S 
 
G SOCIAL PHOBIA (Social Anxiety Disorder) Current (Past Month)   300.23  F40.1  S 
 
H OBSESSIVE-COMPULSIVE DISORDER Current (Past Month)   300.3  F42.8  S 
 
I POSTTRAUMATIC STRESS DISORDER Current (Past Month)   309.81  F43.1  S 
  
J ALCOHOL DEPENDENCE Past 12 Months   303.9  F10.2x S 
 ALCOHOL ABUSE Past 12 Months   305.00  F10.1  S  
 
K SUBSTANCE DEPENDENCE (Non-alcohol) Past 12 Months   304.00-.90/305.20-.90 F11.1-F19.1 S 
 SUBSTANCE ABUSE (Non-alcohol) Past 12 Months   304.00-.90/305.20-.90 F11.1-F19.1 S 
 
L PSYCHOTIC DISORDERS Lifetime   295.10-295.90/297.1/ F20.xx-F29 S 
  Current   297.3/293.81/293.82/ 
     293.89/298.8/298.9 
  
MOOD DISORDER WITH PSYCHOTIC FEATURES Lifetime   296.24/296.34/296.44         F32.3/F33.3/ S              
 Current    296.24/296.34/296.44      F30.2/F31.2/F31.5   
                                   F31.8/F31.9/F39 S  
   
M ANOREXIA NERVOSA Current (Past 3 Months)  307.1  F50.0  S 
 
N BULIMIA NERVOSA Current (Past 3 Months)  307.51  F50.2  S 
 
 ANOREXIA NERVOSA, BINGE EATING/PURGING TYPE Current   307.1  F50.0  S 
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O GENERALIZED ANXIETY DISORDER Current (Past 6 Months)  300.02  F41.1  S 
 
P ANTISOCIAL PERSONALITY DISORDER Lifetime   301.7  F60.2  S 
 Optional 
 
 Which problem troubles you the most?  Indicate your response by checking the appropriate check box(es).  
 
NEUROCOGNITION AND DISABILITY IN PATIENTS WITH 
SCHIZOPHRENIA COMPARED WITH HEALTHY 
CONTROLS 
 
PATIENT PROFORMA 
 
Name 
 
Age 
 
Sex 
 
Marital status 
 
Educational status 
 
Occupation 
 
Duration of illness 
 
Number of hospitalisation 
 
Duration of treatment 
 
Treatment details 
 
 
 
PANSS score 
 
IDEAS disability percentage score 
 
 
 
 
 
 
 
 
 
 S.No TESTS PERCENTILE 
SCORE 
PERCENTILE SCORE 
  
1 Digit symbol substitution TT    
2 Digit vigilance TT  ERRORS  
3 COWA ANW    
4 Animal naming TNW    
5 Verbal N back HITS  ERRORS  
6 Stroop test SE    
7 Auditory verbal learning 
test 
MS  MISSES  
FALSE 
ALARM 
 
8 Comlpex figure test     
 
IDEAS SCORING SHEET 
ITEMS 0 1 2 3 4 
SELF CARE      
INTERPERSONAL 
ACTIVITIES 
     
COMMUNICATION & 
INTERACTION 
     
WORK      
TOTAL SCORE      
DOI SCORE      
GLOBAL SCORE      
 
 DIGIT SYMBOL SUBSTITUTION TEST 
 
1 2 3 4 5 6 7 8 9 
— ┴  L U O Λ X = 
 
 
2 1 3 7 2 4 8 1 5 4 2 1 3 2 1 4 2 3 5 2 3 1 4 6 3 
                         
 
 
1 5 4 2 7 6 3 5 7 2 8 5 4 6 3 7 2 8 1 9 5 8 4 7 3 
                         
 
 
6 2 5 1 9 2 8 3 7 4 6 5 9 4 8 3 7 2 6 1 5 4 6 3 7 
                         
 
 
9 2 8 1 7 9 4 6 8 5 9 7 1 8 5 2 9 4 8 6 3 7 9 8 6 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DVT 
9 5 3 6 4 7 2 8 1 9 2 8 6 2 4 1 2 4 6 8 9 7 3 5 1 8 5 4 2 9 
8 4 2 1 3 5 6 1 9 7 5 6 3 8 2 3 9 7 4 1 2 3 4 5 6 7 8 9 1 2 
1 7 4 8 6 3 2 9 7 1 4 3 2 5 9 5 7 8 6 3 4 5 6 1 7 2 8 3 9 4 
6 1 3 2 9 4 6 5 8 7 3 1 9 5 1 7 5 9 8 1 7 2 8 3 9 4 1 5 2 6 
4 6 7 1 5 3 2 9 1 8 6 4 2 8 6 9 3 1 5 3 1 4 2 5 3 6 4 7 5 8 
2 3 8 2 6 9 7 4 9 1 3 8 6 9 2 2 1 3 8 6 3 7 4 8 5 9 6 1 7 2 
5 8 9 3 1 7 2 6 8 4 1 3 5 7 9 4 8 2 9 4 8 5 9 6 1 7 2 8 3 9 
3 9 1 4 2 6 8 7 5 1 3 2 4 6 8 6 6 4 1 1 8 5 2 9 6 3 1 7 4 2 
6 2 3 5 7 9 1 4 8 2 4 1 3 7 9 8 2 5 2 9 3 1 7 4 2 5 7 6 3 5 
9 2 5 6 1 3 7 2 4 6 1 7 8 3 5 9 4 6 3 1 8 5 2 9 6 3 1 4 2 7 
8 3 7 8 2 6 4 9 1 5 7 2 4 6 8 7 9 8 4 6 9 1 4 7 1 2 5 8 4 3 
7 4 9 7 1 3 5 2 4 6 9 8 1 3 7 5 7 9 6 1 6 3 8 4 9 5 1 6 2 7 
4 5 2 9 2 1 3 7 9 8 2 6 2 4 1 3 5 7 8 3 7 8 3 9 4 1 5 2 6 7 
2 6 4 1 9 4 3 5 7 1 4 7 3 1 4 1 3 9 5 7 8 1 6 2 7 3 8 4 9 5 
5 7 6 3 1 9 6 5 6 3 5 8 6 2 5 8 1 7 9 5 9 2 4 6 8 1 3 5 7 9 
3 8 2 5 6 4 2 8 7 2 6 9 7 3 8 6 2 8 7 9 1 2 3 5 3 9 1 7 3 4 
2 9 8 7 1 3 5 7 9 8 4 2 6 9 7 4 8 6 1 2 3 4 5 7 8 4 6 2 8 9 
1 7 4 9 5 6 8 3 2 1 3 5 7 8 2 2 6 5 3 4 2 6 7 9 4 1 2 8 4 5 
6 5 8 2 1 3 9 7 4 9 7 5 3 1 8 5 4 3 2 6 4 8 9 2 9 5 7 3 9 1 
4 6 3 4 9 2 5 8 2 5 2 8 5 2 3 3 1 4 5 8 5 1 2 4 5 2 3 9 5 6 
5 4 5 6 8 1 4 7 1 6 3 9 6 4 5 7 2 1 4 1 6 3 4 6 1 6 8 4 1 2 
3 2 7 8 6 9 3 6 1 7 4 1 7 6 7 9 3 2 6 2 7 5 6 8 6 3 4 1 6 7 
1 3 9 5 4 8 2 5 2 8 5 2 8 8 9 4 5 1 7 3 8 7 8 1 2 7 9 5 2 3 
9 1 8 3 5 7 1 4 3 9 6 3 9 1 2 6 4 2 8 4 1 9 1 2 7 4 5 2 7 8 
6 4 2 9 3 6 9 3 4 1 7 4 1 3 4 2 6 3 9 5 2 1 3 4 3 8 1 6 3 4 
9 5 3 6 4 7 2 8 1 9 2 8 6 2 4 1 2 4 6 8 9 7 3 5 1 8 6 4 2 9 
8 4 2 1 3 5 6 1 9 7 5 6 3 8 2 3 9 7 4 1 2 3 4 5 6 7 8 9 1 2 
1 7 4 8 6 3 2 9 7 1 4 3 2 5 9 5 7 8 6 3 4 5 6 1 7 2 8 3 9 4 
6 1 3 2 9 4 6 5 8 7 3 1 9 5 1 7 5 9 8 1 7 2 8 3 9 4 1 5 2 6 
4 6 7 1 5 3 2 9 1 8 6 4 2 8 6 9 3 1 5 3 1 4 2 5 3 6 4 7 5 8 
2 3 8 2 6 9 7 4 9 1 3 8 6 9 2 2 1 3 8 6 3 7 4 8 5 9 6 1 7 2 
5 8 9 3 1 7 2 6 8 4 1 3 5 7 9 4 8 2 9 4 8 5 9 6 1 7 2 8 3 9 
3 9 1 4 2 6 8 7 5 1 3 2 4 6 8 6 6 4 1 1 8 5 2 9 6 3 1 7 4 2 
6 2 3 5 7 9 1 4 8 2 4 1 3 7 9 8 2 5 2 9 3 1 7 4 2 5 7 6 3 5 
9 2 5 6 1 3 7 2 4 6 1 7 8 3 5 9 4 6 3 1 8 5 2 9 6 3 1 4 2 7 
8 3 7 8 2 6 4 9 1 5 7 2 4 6 8 7 9 8 4 6 9 1 4 7 1 2 5 8 4 3 
7 4 9 7 1 3 5 2 4 6 9 8 1 3 7 5 7 9 6 1 6 3 8 4 9 5 1 6 2 7 
4 5 2 9 2 1 3 7 9 8 2 6 2 4 1 3 5 7 8 3 7 8 3 9 4 1 5 2 6 7 
2 6 4 1 9 4 3 5 7 1 4 7 3 1 4 1 3 9 5 7 8 1 6 2 7 3 8 4 9 5 
5 7 6 3 1 9 6 5 6 3 5 8 6 2 5 8 1 7 9 5 9 2 4 6 8 1 3 5 7 9 
3 8 2 5 6 4 2 8 7 2 6 9 7 3 8 6 2 8 7 9 1 2 3 5 3 9 1 7 3 4 
2 9 8 7 1 3 5 7 9 8 4 2 6 9 7 4 8 6 1 2 3 4 5 7 8 4 6 2 8 9 
1 7 4 9 5 6 8 3 2 1 3 5 7 8 2 2 6 5 3 4 2 6 7 9 4 1 2 8 4 5 
                              
Time taken:        Errors: S_____   
O_____ 
 
AUDITORY – VERBAL LEARNING TEST 
English Version 
   S.No.  LIST-A  Trial 1  Trial 2  Trial 3  Trial 4  Trial 5  LIST B  IR-A  DR-A Recognition 
1 Arm 
 
     Shoes    Hits 
2 Cat 
 
     Monkey    Mirror 
Hammer 
Knife 
Candle 
Motorcycle 
Axe 
Clock 
Chair 
Plane 
Turtle 
Leg 
Dog 
Table 
Cat 
Lips 
Tree 
Arm 
Nose 
Sun  
Truck 
Eye 
Fish 
Ear 
Horse 
Bike 
Stool 
Bus 
Bed 
Car 
3 Axe 
 
     Bowl    
4 Bed 
 
     Cow    
5 Plane 
 
     Finger    
6 Ear 
 
     Dress    
7 Dog 
 
     Spider    
8 Hammer 
 
     Cup    
9 Chair 
 
     Bee    
10 Car 
 
     Foot    
11 Eye 
 
     Hat    
12 Horse 
 
     Butterfly    
13 Knife 
 
     Kettle    
14 Clock 
 
     Mouse    
15 Bike 
 
     Hand    
            
 TOTAL           
            
 
Total Scores 
 Trial 1  Trial 2  Trial 3  Trial 4  Trial 5 List B IR-A DR Recognition 
 
 
       HITS  
 
 
       OMISSION  
        COMMISSION  
 
 
 
 
 
 
 
 
 
AUDITORY – VERBAL LEARNING TEST 
Tamil Version 
   S.No.  LIST-A  Trial 1  Trial 2  Trial 3  Trial 4  Trial 5  LIST B  IR-A  DR-A Recognition 
1 Kendakai 
 
     Kaalani    Hits 
2 Poonai 
 
     Korangu    Kannadi 
Suthiyel 
Kathee 
Melaguvarthi 
Scooter 
Kodali 
Gadikaram 
Narkali 
Vannurthi 
Aamey 
Kaalu 
Naayi 
Mejai 
Poonai 
Udhadu 
Maram 
Kendakai 
Mooku 
Sooryan 
Lorry 
Kannu 
Meen 
Kadhu 
Kudurai 
Bike 
Stool 
Perundhu 
Padukai 
Car 
3 Kodali 
 
     Kinnam    
4 Padukai 
 
     Maadu    
5 Vaanurthi 
 
     Viral    
6 Kathu 
 
     Aadai    
7 Nayi 
 
     Ettukalpuchi    
8 Suthiyel 
 
     Tumbler    
9 Narkali 
 
     Theynee    
10 Car 
 
     Paadham    
11 Kannu 
 
     Thopi    
12 Kudirai 
 
     Pattampuchi    
13 kathee 
 
     Kettle    
14 Gadikaram 
 
     Eli    
15 Bike 
 
     Kai    
            
 TOTAL           
            
 
Total Scores 
 Trial 1  Trial 2  Trial 3  Trial 4  Trial 5 List B IR-A DR Recognition 
 
 
       HITS  
 
 
       OMISSION  
        COMMISSION  
 
 
 
 
 
 
 
 
ANIMAL NAMING TEST 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                      Total Score:  
 
COWA TEST 
F (ka) A (pa) S (ma) 
   
Total: Total: Total: 
 
Average no. of new words: 
 
 
STROOP TEST 
Stroop effect score = Time taken to name (sec) – Time taken to read the word               
( C – W) 
 
 VERBAL WORKING MEMORY 
 
 
               1 BACK                                                                         2 BACK                                            
 
1 GA  
2 JA  
3 JA  
4 CHA  
5 HA  
6 HA  
7 SHA  
8 RA  
9 NA  
10 MA  
11 MA  
12 KA  
13 PA  
14 PA  
15 LA  
16 VA  
17 TA  
18 TA  
19 LA  
20 PA  
21 VA  
22 VA  
23 DA  
24 DA  
25 CHA  
26 SHA  
27 SHA  
28 GA  
29 YA  
30 YA  
 
  
H 
 
O 
 
C 
 
ERROR 
(O+C) 
 
1 BACK 
    
 
2 BACK 
    
1 NA  
2 GA  
3 NA  
4 MA  
5 LA  
6 JA  
7 LA  
8 MA  
9 KA  
10 LA  
11 KA  
12 JA  
13 YA  
14 MA  
15 YA  
16 DHA  
17 BHA  
18 DHA  
19 VA  
20 SHA  
21 VA  
22 GA  
23 VA  
24 GA  
25 DA  
26 NA  
27 DA  
28 CHA  
29 RA  
30 MA  
RED BLUE  GREEN RED BLUE 
GREEN GREEN RED BLUE GREEN 
BLUE RED BLUE GREEN RED 
GREEN BLUE RED RED BLUE 
RED RED GREEN BLUE GREEN 
BLUE GREEN BLUE GREEN RED 
RED BLUE  GREEN BLUE GREEN 
BLUE GREEN RED GREEN RED 
GREEN RED BLUE RED BLUE 
BLUE GREEN GREEN BLUE GREEN 
GREEN RED BLUE RED RED 
RED  BLUE RED GREEN BLUE 
GREEN RED BLUE RED GREEN  
BLUE BLUE RED GREEN RED 
RED GREEN GREEN BLUE BLUE 
BLUE BLUE RED GREEN RED 
RED GREEN BLUE RED GREEN 
GREEN RED GREEN BLUE BLUE 
RED  BLUE  RED GREEN RED 
GREEN RED GREEN BLUE GREEN 
 
 
 
 
 
 
 
rptg;G      ePyk;  gr;ir  rptg;G                
ePyk; 
gr;ir  gr;ir       rptg;G      ePyk;          
gr;ir 
ePyk;  rptg;G     ePyk;  gr;ir                  
rptg;G     
gr;ir           ePyk;  rptg;G      rptg;G            
ePyk;   
rptg;G      rptg;G     gr;ir            ePyk;  
 gr;ir  
ePyk;  gr;ir   ePyk;  gr;ir                 
rptg;G     
rptg;G    ePyk;  gr;ir  ePyk;  gr;ir 
ePyk;  gr;ir   rptg;G    gr;ir                
rptg;G   
gr;ir         rptg;G   ePyk;  rptg;G          
ePyk; 
ePyk;  gr;ir   gr;ir            ePyk; 
 gr;ir 
gr;ir  rptg;G   ePyk;  rptg;G        rptg;G   
rptg;G   ePyk;  rptg;G    gr;ir                 
ePyk; 
gr;ir  rptg;G  ePyk;  rptg;G           gr;ir 
ePyk;  ePyk; rptg;G   gr;ir     rptg;G 
rptg;G    gr;ir   gr;ir           ePyk; 
      ePyk;  
ePyk;  ePyk; rptg;G   gr;ir             rptg;G 
rptg;G    gr;ir   ePyk;  rptg;G         
gr;ir 
gr;ir  rptg;G   gr;ir            ePyk;       
ePyk; 
rptg;G ePyk; rptg;G    gr;ir          rptg;G   
gr;ir            rptg;G   gr;ir           
ePyk;  gr;ir 
 
 
